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STATEMENT OF ORIGINALITY 
 All the experiments described in this report have been performed by me, and are, to 
the best of my knowledge, original research, which has not been carried out elsewhere. 
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ABSTRACT 
Varicose Veins (VV) affect 10-40% of 30-70 year olds. They have a prominent 
twisted appearance caused by changes in vein wall thickness. Primary weakening of the vein 
wall, due to an imbalance in matrix metalloproteinase enzymes (MMP) and their inhibitors 
(TIMP), is thought to have a major role in homeostasis of extracellular matrix. This could 
cause dilatation of the vessel wall and dysfunction of the valve cusps resulting in reflux. This 
could be contributed to by other factors such as an inflammatory response involving cytokine-
mediated cellular infiltration and/or hypoxia. 
My study examined mRNA expression in VVs, compared with veins from other 
sources (VOS), of MMP and TIMP with pro-inflammatory and pro-angiogenic cytokines 
(TNF-α, IL-1β, IL-6 and VEGF). In parallel I examined expression of hypoxia-regulated 
transcription factors (HIF). Cell culture was performed on Human Saphenous Vein 
Endothelial Cells (HSVEC) and HMEC-1 cells exposed to differing degrees of hypoxia. 
I have shown a significant difference between VVs and VOS in expression of TIMP-
2, -3 and IL-1β. I have demonstrated a significant correlation between VEGF and TIMP-3, 
TNF-α and MMP-2, MT1-MMP, TIMP-2 and TIMP-3 and IL-1β and MMP-2, MT1-MMP 
and TIMP-2. This study has also described, for the first time, HIF-1α and HIF-2α expression 
in VV, and shows that mRNA for both HIFs is significantly reduced in VVs when compared 
to VOS. HIF-1α significantly correlates with MMP-2, TNF-α and IL-1β, whereas HIF-2α 
significantly correlates with MT1-MMP and TNF-α. Cell culture studies revealed little 
difference between different times of hypoxic exposure on mRNA expression of MMP-2, 
MT1-MMP and TIMP-2 in either cell type. However there was a significant increase in 
TIMP-3 as the degree of hypoxia increased. 
These data suggest that alterations in MMP/TIMP, possibly favouring matrix 
degradation leading to vein wall weakness and dilatation, may be mediated both by changes 
in inflammatory signals and/or by alterations in oxygen tension. 
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1 INTRODUCTION 
This project aimed to identify potential explanations for the pathophysiology of 
varicose veins. Varicose veins pose a major clinical problem in western society. This study 
concentrated on finding the effect in changes in matrix metalloproteinases (MMP) and their  
tissue inhibitors (TIMP), and assessed their potential relationship with inflammatory 
cytokines and growth factors. Furthermore the potential relationship between these factors 
and low oxygen concentration was addressed. 
This introduction will have two approaches; a brief description on the clinical features 
and medical management of varicose veins and a more in-depth report focussing on the 
scientific attributes and literary evidence related to varicose veins. 
 
1.1 DEFINITION OF VARICOSE VEINS 
A varicose vein is a vein that is permanently dilated and has become enlarged. They are 
described as dilated, twisted, tortuous and elongated and are usually blue or dark purple. The 
term commonly refers to veins on the leg although varicose veins can occur anywhere. It is 
often assumed that small intradermal subcutaneous veins are varicose veins; however this is a 
misconception. 
1.1.1 ANATOMY OF LOWER LIMB VEINS 
Veins are the conduits for the transport of blood from the tissues back to the heart. 
Within the lower limbs, the venous system is classified as deep and superficial, with 
communicating veins connecting the two. There are two main points where these 2 systems 
meet, namely the saphenopopliteal and the saphenofemoral junctions. 
The superficial veins of the lower limb begin as the dorsal venous arch of the foot. 
This is continuous with two primary veins, the greater and the small saphenous vein. Both of 
these veins contain valves which prevent the reflux of blood and aid the return of blood to the 
body. The valves are bicuspid in shape and more abundant distally. The greater saphenous 
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vein (GSV) is on the medial side. It receives blood from the dorsal venous arch which then 
heads upwards, travelling anterior to the medial malleolus, up the leg, through the knee region 
on the posterior aspect of the medial condyle of the femur, then turns anteriorly and laterally 
as it travels up the thigh. The GSV travels through the saphenous opening, a passageway in 
the fascia of the femoral triangle, to drain into the femoral vein. Along its course the GSV 
receives tributaries from the dorsum of the foot, the heel, the front of the leg, and anterior, 
medial and lateral portions of the thigh. Before emptying into the femoral vein, the GSV 
receives the superficial epigastric, superficial circumflex iliac and superficial external 
pudendal veins. The small saphenous vein (SSV) is on the lateral side. It runs posterior to the 
lateral malleolus and up the middle of the back of the leg. It usually pierces the crural fascia 
about halfway up the leg, running the rest of the way deep to the fascia. In most cases, the 
SSV terminates in the popliteal vein. This is displayed pictorially in Figure 1.1 
Figure 1.1 Anatomy of the venous system in the lower limb 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Perforating veins direct blood from the superficial to deep veins. The deep veins are 
surrounded by muscles and have valves as well. As the muscles contract, they actually pump 
the blood back toward the heart because of these valves. Valves in the perforating veins 
MD (Res) Thesis Beverley Saunders 
Chapter 1 
 18
prevent backflow to the superficial veins. When the valves in the perforators fail, all of the 
superficial blood and some of the blood from deep structures is forced into the superficial 
veins. Because of the hydrostatic pressure and the blood being forced by the muscles into the 
superficial veins, the valves in the superficial veins then fail and the veins become varicose. 
The deep veins of the lower limb consist of paired anterior tibial, posterior tibial and peroneal 
veins that parallel the course of the arterial system. These veins join into the popliteal vein. 
Once the popliteal vein passes through the adductor canal, it becomes the femoral vein. The 
deep femoral vein is a branch of the femoral vein. After receiving branches from the 
saphenous vein, the femoral vein continues as the common femoral vein. Veins from the 
gastrocnemius and soleus muscles are also part of the deep venous system. 
The incompetence of these veins can be due to a failure of the deep venous system, 
superficial venous system and/or the perforating veins, all of which can lead to raised venous 
pressure in the lower limb. Varicose veins can further be divided into primary (no identifiable 
cause) or secondary (arise as a consequence of another disease process). 
1.1.2 VARICOSE VEIN MILESTONES IN HISTORY 
The origin of the word “varicose” probably comes from the Greek meaning 
“grapelike”. It is thought to have been first used as a medical description by Hippocrates in 
460BC. 
The first written record and treatment suggestions for varicose veins were found in 
ancient Egypt in the Ebers papyrus around 1550 BC. They described early attempts at surgery 
and suggested that an operation on these “serpentine windings” would cause fatal 
haemorrhage. 
The first illustration of a varicose vein was discovered in Greece at the foot of 
Acropolis. It is a commonly reproduced votive tablet that shows a large leg with a tortuous 
varicose vein on its medial aspect and dates back to the 4th Century BC. The Hippocratic 
Treatises (460BC) describes a surgical treatment of multiple punctures followed by 
compression. Hippocrates also describes the use of cautery in surgery and is quoted to have 
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said “what cannot be cured by medicaments is cured by the knife, what cannot be cured by 
the knife is cured by the searing iron, whatever this cannot cure must be considered 
incurable”. 
The first ligation of blood vessels was described by the Alexandrian School of 
medicine in Egypt around 270BC. Celsus, a roman physician in the 1st century AD treated 
varicose veins by excision and cauterisation and described ligation of bleeding veins and 
division of veins between ligatures. Galen used silk ligatures to tie off blood vessels and 
suggested that varicose veins should be treated by incision and avulsion with the use of hooks 
(phlebectomies), a technique that is still used today.  
By the 13th century there was a lot of progress in anatomy, physiology, surgical 
procedures and techniques which have expanded greatly and become more refined. Surgeons 
in this era were beginning to perform routine operations. 
The 15th century brought new interest in venous anatomy because of Leonardo da 
Vinci’s drawings of the human body and in the 16th century the anatomy of the venous system 
was presented in great detail in the works of Andreas Vesalius.  
The 16th century brought the discovery of valves. Venous valves were probably first 
mentioned by J B Canano who described the valvular fold in the azygos vein in 1547. Others 
have been recognised for their drawings of valves but the first full description of valves was 
given by Hieronymus Fabricus de Aquapendente, Professor of Anatomy of the medical school 
in Padua in 1603. In 1628 William Harvey published the discovery of circulation. He wrote 
“blood moves in the veins from parts below to those above and to the heart, and not in the 
opposite way”. 
The 1800s lead to further understanding of the venous system but more with regards 
aetiologies and consequences of an acute venous thrombosis. However, John Gay’s 
Lettsomian Lectures published in 1866 contain accurate descriptions of perforating veins in 
patients with varicosities and ulcerations and also suggests that treatment of varicose veins 
results in the healing of ulcers.  
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In the early 20th century stripping of the GSV was performed in addition to the 
proximal ligation that was originally described by Trendelenburg in the 1890’s. In 1905 
Keller describes the use of an internal stripper and Mayo describes an external ringed vein 
stripper in 1906. Babcock’s contribution was the development of a flexible internal saphenous 
stripper slightly later. Later on around the middle of the century suggestions were made for 
perforator vein surgery as a management for varicose ulcers due to incompetent 
communicating veins and approximately 30 years after this venous valve reconstructions were 
also successful in the deep venous system for management of deep venous incompetence. 
In the past 3 decades thrombolysis, endovascular intervention methods, venous 
angioplasty and stents are rapidly improving the ability to treat the deep venous system. The 
earlier methods as described above, until very recently, were still common place in the 
practice of managing varicose veins. However treatment now readily consists of minimally 
endovenous procedures which is making the operation originally described by Trendelenburg 
a thing of the past (Rutherford). 
 
1.2 EPIDEMIOLOGY OF VARICOSE VEINS 
1.2.1 INCIDENCE AND PREVALENCE OF VARICOSE VEINS 
Prevalence of varicose veins in the Western population over the age of 15 years has 
been estimated at between 10-15% for men and 20-25% for women (Callam 1994). 
Prevalence has been reported to vary widely by geographical location, with the highest 
reported rates in Western countries (Beebe-Dimmer et al. 2005). This could possibly be 
explained by environmental factors in the western world such as low fibre diet and lack of 
exercise. Carpentier et al compared the prevalence of varicose veins and chronic venous 
disease within France at 4 different locations. Within this one country he showed a high 
prevalence of both varicose vein disease and chronic venous disorders but this showed no 
significant geographical variation (Carpentier et al. 2004). 
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1.2.2 RISK FACTORS FOR VARICOSE VEINS 
Evidence linking many assumed risk factors to the development of varicose vein 
disease is limited. Although it is repeatedly reported that the incidence of varicose veins is 
more common in women it has been found that being female is not a strong risk factor 
(Jawien 2003). The general consensus is that the most apparent risk factors for this disease are 
Parity and Weight. Studies suggest that women who have had 2 or more pregnancies were at 
increased risk of developing varicose veins (da Silva et al. 1974; Maffei et al. 1986; Brand et 
al. 1988). It is commonly assumed that the enlarged uterus impairs venous return and 
therefore increases the venous pressure in the lower limbs. This does not explain why the 
majority of varices appear very early on in pregnancy so other factors must play a key role 
such as alterations in hormone balance or increased circulating blood volume. Both the 
Framingham study as well as a community survey in West Jerusalem confirmed that people 
with a higher Body Mass Index were more likely to have venous disease (Abramson et al. 
1981; Brand et al. 1988). The Basle Trial also reports this but only in females (da Silva et al. 
1974). 
There is conflicting evidence as to whether age, family history, constipation and 
prolonged sitting or standing/lack of exercise may play a key role in the development of 
varicose veins.  
Again evidence is inconclusive but trauma to the lower limb in the form of a deep vein 
thrombosis or fracture would understandably cause stress on the venous system and increase 
the risk of varicose vein formation. 
 
1.3 SYMPTOMS AND DIAGNOSIS 
For most individuals, varicose veins do not inflict any symptoms and never cause any 
harm. The most common complaint, especially in females, is that they are not aesthetic. 
Campbell et al performed a questionnaire study on a population of patients who had been 
referred for hospital assessment of uncomplicated primary varicose veins. They found that 
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many people were anxious of the potential harm their veins could inflict on them. 
Specifically, fears included thrombosis, trauma, ulcers and other more general concerns about 
the future. In this group of patients, many of these worries are inappropriate and with good 
management including specific enquiry and reassurance about these concerns, unnecessary 
treatment may be avoided (Campbell et al. 2006).Varicose veins can cause a wide range of 
symptoms but the most common complaints include discomfort, heaviness, achiness and 
itching, mainly in the lower limb. This was confirmed by the Edinburgh Vein Study however 
the relationship between the distribution of the incompetent vein and the symptoms were 
inconsistent; specifically in males (Bradbury et al. 1999). The symptoms are often 
exaggerated after prolonged standing, walking or towards the end of the day. Patients usually 
report an element of relief on elevation of the legs. Leg swelling is another complaint but this 
is much less common (Campbell 2006). A proportion of patients with varicose veins will 
develop serious complications including superficial and deep vein thrombosis (DVT), 
superficial thrombophlebitis, skin thickening and staining (lipodermatosclerosis), 
haemorrhage and in the most severe scenario, ulceration. These changes in the skin and the 
subcutaneous tissues are often referred to clinically as chronic venous insufficiency (CVI) or 
chronic venous disease (CVD) and this warrants serious consideration for treatment as it 
associated with increased venous pressure. These complications together with the fact that 
varicose veins are one of the commonest reasons for surgical intervention in the Western 
world explains why venous diseases absorb approximately 1% of hospital in patient costs in 
major EU countries. 
1.3.1 CLINICAL EXAMINATION AND INVESTIGATION 
Clinical examination alone, in straightforward cases, can reveal all the information 
required to make a clear diagnosis and compile a management plan. Inspection, both lying 
and more specifically standing and visualising both the front and the back of the leg, is vitally 
important. This will provide the clinician with the extent, size and distribution (e.g. GSV 
and/or SSV involvement) of the disease. It is important to look at the skin, especially the 
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lower leg on the medial aspect (the gaiter area) for venous eczema, skin discolouration, ulcers 
or swelling, and also in the groin for scars indicating previous surgery.  
Palpation of the saphenofemoral junction will inform the clinician of whether or not a 
sapheno varix is present. If it is, the cough test may be positive (Cruveilhier’s sign). 
Traditionally specific examinations include the Trendelenburg test and the tourniquet 
test which both involve lying the patient down with the leg lifted so as to drain the venous 
system of blood (the leg may require some gentle squeezing to facilitate this) and then 
palpating and occluding the saphenofemoral junction with gentle pressure using either a hand 
or a tourniquet. The patient is then asked to stand up. If there is rapid filling of the varicosities 
with the saphenofemoral junction controlled, either by pressure or tourniquet, then this 
suggests there are incompetent perforator veins. If no filling is seen then the pressure can be 
released. If there is rapid filling of the varicosities at this stage then this is suggestive of 
saphenofemoral junction incompetence. The advantage of using the tourniquet is that it can be 
placed in the mid-thigh region in order to examine different levels of perforator veins. It is 
more likely these days that a clinician would use a hand held Doppler to identify 
saphenofemoral or popliteal fossa reflux by holding the Doppler over the respective junctions 
and squeezing the thigh or the calf and listening to the proximal blood flow up the leg and 
waiting to see whether there is a second “whoosh” that occurs with incompetent veins as 
blood refluxes back down the leg. 
Duplex ultrasound is a painless procedure that combines Doppler flow information and 
conventional imaging information in order to see the anatomy of blood vessels. Duplex 
ultrasound shows how blood is flowing through vessels and measures the speed of the flow of 
blood. It can also be useful to estimate the diameter of a blood vessel as well the presence of 
an occlusion. It is performed by specialists within that field called Vascular Scientists. Some 
specialists would prefer all patients to have duplex imaging, however, other units limit the 
scanning for specific indications like a previous history of DVT, ulceration, recurrent varicose 
veins or differentiating whether the disease is in the greater saphenous or short saphenous 
region, as occasionally this can be ambiguous. All patients with SSV disease must be imaged 
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by this modality as the anatomy varies greatly in this area, so before operation must be 
marked. 
 
1.4 TREATMENT OF VARICOSE VEINS 
1.4.1 CONSERVATIVE METHODS 
For patients who are mildly symptomatic from varicose vein disease it is reasonable to 
offer conservative management. Good explanation, reassurance that their condition is unlikely 
to cause them harm and that operative treatment is not essential, will often suffice. 
Conservative approaches may improve mild symptoms. These include wearing graduated 
compression stockings with pressure of 30-40mmHg, leg elevation, regular exercise (although 
there is no evidence to support this (Chant et al. 1985) and weight loss. 
1.4.2 TRADITIONAL SURGICAL TREATMENT 
However for patients with significant symptoms, who have failed to get relief from 
conventional efforts or have substantial venous insufficiency, open surgery has been the 
treatment of choice for many years. It involves saphenofemoral (see Section 2.1.4 for in-depth 
description of the operation) or saphenopopliteal disconnection and stripping of either the 
greater or SSV and removal of superficial varicosities. By doing this venous reflux is 
eliminated and superficial venous pressure is reduced to near normal levels. 
1.4.3 ENDOLUMINAL TREATMENT METHODS 
1.4.3.1 Sclerotherapy 
Sclerotherapy is considered the treatment of choice for small intradermal 
subcutaneous veins, however, it is now also considered an effective treatment for the 
significant reflux associated with varicose vein disease (Berridge et al. 2009; Coleridge Smith 
2009). Despite this it still tends to be only used in patients that require further intervention for 
residual varicosities after having an alternative surgical procedure or in those who are unfit or 
do not want surgery.  
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It involves injection of a chemical, in either liquid or foam form, directly into the 
vein. The chemical irritates and scars the vein from the inside out so that the abnormal veins 
can then no longer fill with blood. Blood that would normally return to the heart through these 
veins returns to the heart through other veins. The body will eventually absorb the redundant 
vein. 
Results are better if the procedure is performed under Ultrasound guidance, if a foam 
agent is used as the sclerosant and if the vein is smaller rather than larger.  
1.4.3.2 Radiofrequency Ablation 
Radiofrequency ablation uses a thin, flexible tube with a tiny bipolar electrode at its 
tip that is inserted into a varicose vein. When the high frequency alternating current is 
triggered it inflicts ionic agitation and local heating resulting in venous vasospasm and intimal 
destruction. This produces a fibrotic luminal seal.  
The procedure is usually performed under general, regional or tumescent local 
anaesthesia. This technique cannot be performed on veins that are too small to cannulate 
(<2mm), tortuous veins or veins with thrombus in them. 
1.4.3.3 Endovenous Laser Treatment 
This ablation technique is very similar to radiofrequency ablation excepting the 
catheter allows insertion of a laser fibre. The laser energy generates steam bubbles that boil 
the blood in the lumen of the varicose vein and delivers heat injury to the vein wall (Proebstle 
et al. 2002). This procedure is usually performed under perivascular tumescent local 
anaesthesia. 
There is no single appropriate method for treating the range of manifestations in 
venous disease (Subramonia and Lees 2007; Berridge et al. 2009). However, endovenous 
venous ablation techniques are becoming more and more popular and the traditional operation 
is being performed less often in clinical practice. 
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1.5 AETIOLOGY 
1.5.1 POTENTIAL GENETIC LINK IN THE CAUSATION OF VARICOSE VEINS 
No clear genetic link has been found in varicose vein disease. However there has 
been some evidence suggesting a familial susceptibility, thereby warranting future genetic 
studies (Lee et al. 2003). 
Studies have shown a direct correlation between the severity of reflux and the clinical 
symptoms of CVI such as skin colour changes and lipodermatosclerosis (Christopoulos et al. 
1988). Skin staining and lipodermatosclerosis causes iron in the form of haem to be deposited 
into the subcutaneous tissues. Iron deposition is known to increase the concentration of free 
radicals in the surrounding tissue and these results in tissue injury (Zamboni et al. 2005; 
Zamboni et al. 2006). Haemochromatosis is a genetic disorder causing the body to absorb an 
excessive amount of iron from the diet which is then deposited in various organs, mainly the 
liver, but also the pancreas, heart, endocrine glands, and joints. Factor VIII is a cross linking 
protein that is key in ulcer healing. It has been found that gene mutation of the 
haemochromatosis C282Y (HFE) gene and genetic variations of the factor VIII V34L gene 
are present in patients with CVD and varicose veins, thus predisposing them to this condition. 
These patients may have long term implications for increased risk of more severe forms of 
CVD as well as venous ulcers (Zamboni et al. 2005; Tognazzo et al. 2006). 
There are also clinical conditions that in theory would support a genetic link. Klippel-
Trenaunay Syndrome is characterized by a triad of dermal capillary haemangiomas, varicose 
veins, and bony and soft tissue hypertrophy involving an extremity. This syndrome can have a 
number of congenital venous anomalies associated with it such as atresia, agenesis of the deep 
venous system, valvular insufficiency, venous aneurysms and embryonic veins. These 
patients have a significant impairment of venous muscle pump function and valvular 
incompetence (Delis et al. 2007). Another example is Ehlers-Danlos syndrome which is a 
group of ten different types of inherited connective tissue disorders, caused by a defect in the 
synthesis of collagen. Type IV predisposes to vascular pathology and can present with 
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varicose veins. In contrast to this evidence suggesting a genetic link, Marfan's syndrome is a 
autosomal dominant genetic disorder of the connective tissue that is carried on the FBN1 gene 
which encodes a connective protein called fibrillin-1. This is an essential protein for elastic 
fibre synthesis. However, this disorder mainly affects the aorta and the heart valves and is not 
associated with venous disease or varicose veins (McKusick 1991).  
1.5.2 VALVULAR DEFECTS AS A CAUSE FOR VARICOSE VEINS 
Blood reflux and valve dysfunction are central to the progression of venous disease. 
Reflux can occur within many of the venous systems of the lower limb, namely the superficial 
venous system (GSV and SSV), tributary veins, the saphenofemoral and saphenopopliteal 
junctions, the deep venous system and perforator veins (as shown in figure 1.2). Peak vein 
velocity has been found to have no significance in determining reflux. The method of choice 
is the duration of retrograde flow across a valve. The duration of retrograde flow across a 
diseased valve in the superficial and deep calf veins is greater than 0.5 seconds and for the 
femoropopliteal veins should be greater than 1 second. Outward flow in the perforating veins 
should be considered abnormal at greater than 0.35 seconds (Labropoulos et al. 2003). 
 
 
Figure 1.2  Valvular function in normal and varicose veins 
In a normal vein, the valve permits blood to flow in only one direction. In a varicose vein, defective 
valves never fully close, allowing backflow. 
http://hopkins.portfolio.crushlovely.com/reference/article/varicose-veins 
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Labropoulos et al have done a number of studies investigating the location of reflux, 
the tributaries of the main superficial veins and the progression of reflux. They have 
concluded that primary venous reflux can occur in the superficial and the deep venous system 
of the lower limb. It is more common to have reflux below the knee and that this can be the 
case for asymptomatic patients, patients with prominent veins but not varicose and varicose 
vein disease. Because of this anatomical prominence it implies that progression of the disease 
is ascending. Reflux tends to be a local process. However, it can be multifocal which is more 
likely to be associated with worsening disease (Labropoulos et al. 1997). In parallel, they 
performed a study assessing tributary reflux and found that both the greater saphenous system 
and small saphenous system had tributaries which could be affected by reflux and that this 
could occur in the tributaries independently from the GSV, SSV, deep veins or perforator 
veins. This suggests that the tributaries do not have to have a feeding source and can develop 
reflux independently. It did show that the tributaries of the GSV were affected more often 
than the SSV tributaries (Labropoulos et al. 1999). A later study by the same group found that 
approximately a third of patients with confirmed venous reflux will have progression of their 
disease. 15% showed extension of the pre-existing reflux while 12% presented with new areas 
of reflux. On average the progression time to notice this change by Doppler ultrasound, and in 
some cases because of clinical changes, was 6 months. Again, progression was more common 
in the GSV, its tributaries and perforators (Labropoulos et al. 2005). 
To summarise the evidence so far, reflux is suggested to occur segmentally and occur 
in an ascending fashion. Retrograde flow in the lower limb venous system occurs due to 
failure of the valves to function sufficiently. This could occur as primary valve dysfunction, 
in which the aetiology is uncertain or there may be factors occurring within the vein wall that 
could cause the valve function to fail. Several studies have indeed shown significant changes 
in the organisation of the extracellular matrix (ECM) and architecture of the smooth muscle 
cells (SMC) within the varicose vein vessel wall. 
Mashiah et al supports the "weak vein wall" theory concerning the aetiology of 
varicose veins. They examined samples of varicose veins under a scanning electron 
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microscope in 29 women who had undergone surgery under local anaesthesia for 
symptomatic varicose veins. All had been previously diagnosed as having incompetence of 
the valve at the saphenofemoral junction. They found no changes in the intima or adventitia 
and no changes in any of the upper valves of the saphenous vein. There was, however, 
varying degrees of thinning of the media of the venous wall, which coincided with the areas 
of varicose dilatation between areas that retained their normal configuration (Mashiah et al. 
1991).  
Gandhi et al performed a study to evaluate the connective tissue constituents of 
greater saphenous varicosities and also the proteolytic activity, a factor that can lead to matrix 
degradation and cause weakening and dilation of the venous wall. They found a significant 
increase in the collagen content and a significant reduction in the elastin content of varicose 
veins. There was also an increase in the collagen/elastin ratio which is an indication that there 
is an imbalance within the connective tissue matrix. The biochemical profile of potential 
varicose veins was similar to varicose veins and both of these were significantly different 
from normal saphenous vein. When looking at the enzymatic activity there was no increase in 
the proteolytic activity which indicates that there is potentially no essential enzymatic matrix 
degradation in the formation of venous varicosities (Gandhi et al. 1993). Venturi et al aimed 
to find a biochemical explanation to why varices develop. They did this by evaluating 
sensitive biochemical markers of collagen (4-L-Hydroxyproline) and elastin (desmosine and 
isodesmosine) in the varicose vein wall of 20 patients. This was then compared with samples 
taken from 14 patients with normal saphenous veins in whom the vein was removed to be 
used for graft procedures. 4-L-Hydroxyproline and collagen content were similar in varicose 
and normal veins. There was a significant reduction of both desmosine and isodesmosine in 
the dilated segments of varicose veins indicating a reduction in elastin. The ratio of elastin to 
collagen was lower in varicose than normal veins, and this reduction was most significant in 
the dilated segments. These results suggest that dilatation of the varicose vein wall may be 
related to some defect of elastin metabolism (Venturi et al. 1996). Psaila et al measured the 
physical strength and elasticity of varicose veins and compared them to “normal” veins. They 
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found that varicose veins had a lower breaking strength and breaking energy than normal 
veins and that elastic stiffness was less in normal veins than in varicose veins. In the same 
samples they also determined that the collagen content was significantly higher in normal 
vein specimens in all sites examined. Visually, normal veins displayed distinct viscoelastic 
features in the wall around the valves which were absent at other sites. These differences were 
not found in varicose veins. They concluded that significant structural changes are seen in 
varicose veins (Psaila and Melhuish 1989). The objectives of Travers et al were to compare 
collagen and elastin content in varicose and control GSVs by histological staining. Varicose 
veins were significantly larger in wall area and contained increased amounts of collagen. 
There was no difference in wall thickness or elastin content between the two groups (Travers 
et al. 1996). Sansilvestri-Morel et al found an imbalance in collagen subtypes synthesis by 
SMC in varicose vein wall. Their data illustrates that SMC cultured from varicose veins 
deposit less collagen type III and fibronectin than control cells despite comparable levels of 
messenger RNA (mRNA) for these proteins suggesting dysregulation of posttranslational 
steps in the synthesis of both proteins by SMC from varicose veins (Sansilvestri-Morel et al. 
1998). They also evaluated cultured dermal fibroblasts to see whether the changes observed in 
venous SMC were similar. Both these cell types had increased synthesis of type I collagen but 
a decrease in type III (which is important for elasticity and distensibility). This finding is 
evidence that varicose vein patients may have a systemic problem affecting collagen and may 
imply a genetic cause for the disease (Sansilvestri-Morel et al. 2002). They also measured the 
content of hydroxyproline in these cells and quantified the amount of collagen types I, III and 
V. There was an increase in hydroxyproline content which would normally indicate an 
increase in collagen, however, there was a decrease in type III collagen (Sansilvestri-Morel et 
al. 2003).  
There have been many studies investigating the changes in wall matrix proteins and 
their associated components. This is explained in more detail in Section 1.5.3. These studies 
provide further evidence to suggest that alterations in the vein wall precede changes in the 
venous valve during varicose vein formation. 
MD (Res) Thesis Beverley Saunders 
Chapter 1 
 31
1.5.3 WEAKNESS OF THE VEIN WALL AS A CAUSE OF VARICOSE VEINS 
It would make sense that the increase in venous hypertension in the lower limb would 
cause endothelial cell damage/dysfunction (discussed in Section 1.5.3.2) and cause a local 
inflammatory response (Section 1.5.3.4). However, significant inflammation is likely to occur 
at a later stage of the disease and is preceded by other actions on the endothelium and smooth 
muscle (Section 1.5.3.1) e.g. an increase in MMP expression/activity (Section 1.5.3.3) 
(Elsharawy et al. 2007).  
1.5.3.1 Venous Wall Smooth Muscle Changes 
Cultured SMC from varicose veins tissue have been used in a number of studies in 
order to determine whether or not ECM changes are associated with SMC. Sansilvestri-Morel 
et al cultured SMC from varicose veins and also control veins for assessment by 
immunofluorescence. The immunostaining for both collagen type III and fibronectin was 
weaker in cells from varicose veins than in those of control veins despite their transcriptional 
products being similar. Collagen type I deposition was similar in both types of cells while 
collagen type III was decreased in varicose vein cells. They also quantified MMP-1, -2 and -9 
and TIMP-1, by enzyme immunoassays in the supernatants from smooth muscle cell cultures 
postconfluence. No significant difference was observed in the synthesis of any of the MMP or 
their inhibitors tested. This result only reflects what was found in the supernatant and does not 
exclude alterations in expression or activity of MMP or TIMP in whole tissues. These results 
would suggest that the regulation for collagen type III and fibronectin in SMC are post-
transcriptional events (Sansilvestri-Morel et al. 1998). The same authors furthered their 
investigations by adding Marimastat, a non-selective MMP inhibitor, to the SMC. This caused 
a partial restoration in the production of collagen type III. In addition to this, MMP-3 which 
degrade fibronectin, was elevated in both transcription product and protein expression. They 
concluded that collagen III, and probably fibronectin, are degraded extracellularly in SMC 
from varicose veins by a mechanism involving MMP, and maybe MMP-3 by a direct or an 
indirect pathway (Sansilvestri-Morel et al. 2005). So in conclusion, the evidence suggests that 
in varicose vein SMC there is an imbalance in collagen production with dysregulation and 
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increased type I collagen production, but a decrease in type III. The reduction in type III 
collagen is likely to be post transcriptional as it is associated with normal mRNA production. 
Also, it could occur as a result of degradation/inhibition by MMP-3.  
Apoptosis is the process of programmed cell death that may occur in multicellular 
organisms. Programmed cell death involves a series of biochemical events that can occur in 
response to intrinsic signals or extrinsic stimuli. Examples of these apoptosis factors are 
Tumour necrosis factor-α (TNF-α), neurotransmitters, Growth Factor withdrawal, IL-2 
withdrawal, FAS ligands, Radiation, Chemotherapeutic agents, reactive oxygen metabolites, 
viral infection and toxins. Ascher et al hypothesized that abnormal cell cycle events in the 
vein wall may contribute to changes in its structural integrity predisposing to varicosity 
development, and that possibly apoptosis is a contributing factor in the pathophysiology of 
varicosities. They designed a study to investigate whether programmed cell death varies in 
varicosities as compared to normal veins by staining samples immunohistochemically for the 
expression of bcl-2 and cyclin D1 and by detecting apoptosis by the TUNEL assay. The 
apoptotic index was 15% for varicose veins and 48% for control veins. Varicose vein 
specimens demonstrated increased nuclear expression of cyclin D1 whereas its cytoplasmic 
expression was significantly diminished which suggests that programmed cell death is 
inhibited in varicose veins. There was no difference in Bcl-2 protein for either study groups 
(Ascher et al. 2000). They then went on to examine the expression of bax protein and of poly 
ADP-ribose polymerase, which is involved in the repair of DNA damage and is inhibited by 
the activation of caspases 3 and 6. Both bax and poly ADP-ribose polymerase were decreased 
in the distal portion of varicose veins when compared to distal control vein segments. 
Varicose veins had no expression of bax or poly ADP-ribose polymerase in their adventitial 
layer although their expression was detected in this layer of the control group (Ascher et al. 
2001). Together these studies suggest a role of abnormal apoptosis that may in turn lead to 
venous wall changes and dilatation. 
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1.5.3.2 Venous Endothelial Cell Dysfunction 
The role of MMP in varicose veins has largely been attributed to their proteolytic 
effects on the ECM, degradation of the valve leaflets and weakening of the venous wall 
(Herouy et al. 1999; Pascarella et al. 2005). It is now apparent the MMP are present in venous 
SMC as well as the venous endothelium and this suggests the possibility of additional roles 
for MMP in the pathophysiology of venous disease (Thulesius 1996; Woodside et al. 2003). 
Rafetto et al performed studies on the rat inferior vena cava and demonstrated that MMP-2 
causes inhibition of phenylephrine-induced venous contraction. They then wanted to establish 
whether or not MMP-2 induced inhibition of contraction involved the endothelium. They 
concluded that MMP-2 causes a significant inferior vena cava relaxation that is potentiated in 
the absence of endothelium or during blockade of endothelium-mediated nitric oxide and 
prostacyclin synthesis. They also suggested that MMP-2 may induce smooth muscle 
hyperpolarisation and activation of calcium dependant potassium channels that may play role 
in the early stages of venous dilatation and varicose vein formation (Raffetto et al. 2007). 
1.5.3.3 Matrix Metalloproteinases, Their Inhibitors And Their Role In Veins 
Matrix metalloproteinases (MMP or matrixins) are a group of zinc- and calcium-
dependent endopeptidases that play an important role in degrading components of the ECM 
and thereby regulate formation, remodelling and maintenance of tissue. MMP also have a key 
role in migration of normal and malignant cells through the body. These mechanisms are 
important in both normal physiological repair processes as well as disease processes such as 
arthritis and metastasis. Most MMP are extracellular enzymes e.g. collagenases (MMP-1, -8, -
13 and -18), gelatinases (MMP-2 and -9) and stromelysins (MMP-3 and -10). There are, 
however, a group of membrane type MMP (MT-MMP). The basic MMP structure consists of 
a prodomain, catalytic domain, hinge region and hemopexin domain. An example of their 
structure is shown in Figure 1.3. All of these are expressed mainly by connective tissue cells 
and in cells of bone marrow origin as inactive pro-proteins (pro-MMP) which then get 
cleaved by extracellular proteinases that activate them. MMP activity is controlled by 
regulation at the transcriptional level, as well as by zymogen activation and inhibition by 
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specific tissue inhibitors of metalloproteinases (TIMP). So far 4 TIMP (TIMP-1, -2, -3, -4) 
have been identified. The two-domain TIMP are of relatively small size but have been shown 
to exhibit several biochemical and physiological/biological functions including inhibition of 
active MMP, pro-MMP activation, cell growth promotion, matrix binding, inhibition of 
angiogenesis and induction of apoptosis (Brew et al. 2000). An example of their structure is 
shown in Figure 1.4. As is the case for matrixins, the expression of TIMP in tissue is also 
controlled during tissue remodelling and physiological conditions to maintain a balance in the 
metabolism of the ECM (Das et al. 1997; Gomez et al. 1997). 
 
 
 
 
 
 
 
Figure 1.3 History and Domain Structure of MMPs  
Compilation of MMPs. Date of discovery of MMP and amino acid sequence listed in parentheses 
(http://www.abcam.com/index.html?pageconfig=resource&rid=11034) 
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Figure 1.4 TIMP Structure  
Schematic representation of TIMP-1 structure. TIMP-1 contains 12 cysteine residues which form six 
loop structures through disulfide bonds. The N-terminus of TIMPs 1-4 binds to the catalytic domain of 
most activated MMPs and inhibits function. The C-terminus of TIMP-1 and TIMP-2 binds to the 
hemopexin domain of proMMP-2 and proMMP-9, respectively; this binding regulates MMP function. 
(http://www.abcam.com/index.html?pageconfig=resource&rid=11034) 
 
 
 
 
Remodelling of the ECM is an important cause of the changes in the walls of varicose 
veins, and as a result MMP/TIMP have been proposed to play a key role. Studies have 
confirmed the presence of MMP-1, -2, -3, -9, -12, -13 and TIMP-1 and -2 in both normal and 
varicose vein tissue (Gillespie et al. 2002; Woodside et al. 2003). Not all the evidence reports 
the same findings, for example, the presence of MMP-3 in varicose veins is inconclusive. 
Gillespie et al attempted to isolate MMP-3 mRNA in both healthy and varicose veins but 
were unable to get a positive result (Gillespie et al. 2002). However, Kowalewski et al have 
showed that MMP-3 is present in veins, and in increased amounts in varicose veins when 
compared to non-varicose veins. They also isolated MMP-1 MMP-2 and MMP-9 
(Kowalewski et al. 2004). Gillespie et al continued his study into MMP and varicose vein 
tissue and demonstrated that there is an increase in MMP-1 protein in varicose veins segments 
when compared to control vein segments. A post transcriptional cause is likely for this 
observation as both tissue types showed similar mRNA expression. They also showed that 
there is a tendency for regional variation of both MMP-1 and MMP-13 expression in varicose 
veins, in that both these matrixins are more abundant in proximal segments (Gillespie et al. 
2002).  
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In order to assess the localisation of MMP within the varicose vein wall, and 
therefore the potential role in the development of varicosities, immunohistochemistry has 
been performed by a number of groups. Woodside et al confirmed the presence of MMP-1, 
MMP-2, MMP-9, and MMP-12 as well as TIMP-1 and TIMP-2 were confirmed in varicose 
vein tissue as well as control vein tissue by Western blot analysis and then proceeded onto 
looking at the venous architecture and protein localization by histology and 
immunohistochemistry. They observed that varicose veins were not uniformly distributed 
along the circumference; areas of intimal thickening were often interspersed with focal areas 
of dilatation. Fragmentation of elastic lamellae and loss of circular and longitudinal muscle 
fibres were evident in the varicosities. Focal aggregates of macrophages were detected within 
the media and adventitia of both normal and varicose veins. MMP-1 and MMP-9 were 
expressed in both types of vein segments but with different localisation. Normal vein 
expressed MMP-1 in endothelial cells, occasional SMC, and adventitial microvessels whereas 
varicose vein MMP-1 expression was localized to fibroblasts, SMC and endothelial cells. 
MMP-9 was localized to endothelial cells, medial SMC, and adventitial microvessels in both 
normal and varicose veins, although varicose veins demonstrated increased medial smooth 
muscle cell staining. MMP-12 was found in SMC and fibroblasts in both normal and varicose 
veins. Neither TIMP-1 nor TIMP-2 was detected with immunohistochemistry in any 
specimens examined. This confirms that there is a distinct difference in the structural 
architecture and localization of MMP expression in normal and varicose veins (Woodside et 
al. 2003).  
A number of studies have examined at the relationship between TIMP-1 and MMP-2. 
Badier-Commander et al examined 12 varicose veins and ten control veins for proteolytic 
enzyme/inhibitor balance using western blotting, gelatine or plasminogen-casein zymography 
and ELISA techniques. A high TIMP-1 level and a low MMP-2 level/activity were found in 
varicose veins resulting in a three-fold increase in the TIMP-1/MMP-2 ratio in varicose 
versus control veins (Badier-Commander et al. 2000). The same conclusion with reported by 
Parra et al who, with similar methodology al found an increased TIMP-1/MMP-2 ratio in 
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varicose veins (Parra et al. 1998). This may partially explain why there is ECM accumulation 
in varicose veins. The mechanisms involved in the regulation of the MMP/TIMP balance are 
hitherto unknown, but potential candidates include cytokines and/or alterations in oxygen 
tension which are discussed in their own sections. 
I previously stated that Rafetto et al had performed studies on the rat inferior vena 
cava and concluded that MMP-2 inhibits venous contraction potentially through inducing 
smooth muscle hyperpolarisation and activation of calcium dependant potassium channels. 
They went on to test whether or not prolonged increases in venous wall tension causes over-
expression of MMP and decreased contractility which in turn would promote dilation. They 
found that in Rat inferior vena cava, increases in the magnitude and the duration of wall 
tension causes reduced contraction and over-expression of MMP-2 and MMP-9. This would 
suggest that the progression of events entail increased venous pressure and wall tension 
increases that MMP expression which in turn reduced venous contraction and leads to 
progressive venous dilatation (Raffetto et al. 2008). 
1.5.3.4 Inflammatory Changes In The Pathology Of Varicose Veins 
It is thought that leukocyte trapping and activation in the microcirculation of the leg 
skin due to venous hypertension causes lipodermatosclerosis and ulceration in CVD. 
Takase et al performed immunohistochemistry on proximal saphenous vein and 
subterminal valve, which were removed during surgical treatment, in order to detect adhesion 
molecules and cytokines. Their results showed an increase in monocyte/macrophage 
infiltration in the vein wall and valve. They also found an increase in intracellular adhesion 
molecule-1 in the specimens. This molecule promotes adherence of leukocytes to the 
endothelium. Other cytokines were not elevated that not only luminal venous endothelium but 
also endothelium in the vasa vasora of refluxing saphenous veins is activated, as indicated by 
the up-regulation of intracellular adhesion molecule-1. However, there were no consistent 
observations of the cytokines IL-1α and TNF-α (Takase et al. 2000). Sayer et al also looked 
at the localisation of inflammatory infiltrate in varicose veins in comparison to normal 
controls and, similarly to Takase, found that varicose veins had significantly more 
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inflammatory infiltrates in the form of mast cells and macrophages/monocytes in comparison 
to controls. There was also a trend of increased numbers of T-lymphocytes in varicose vein 
(Sayer and Smith 2004). Saharay et al investigated leukocyte endothelial adhesion in patients 
who were subjected to short-term venous hypertension. Blood samples were taken from a foot 
vein before and after standing for 30 minutes to raise the venous pressure in the lower limb, 
and after lying supine again for 10 minutes in 2 groups of patients. The first had varicose 
veins with skin changes and the second varicose veins without skin changes. The samples 
were analyzed for leukocyte surface CD11b and L-selectin (CD62L) expression as well as 
plasma-soluble L-selectin. Their results were very similar within the 2 groups. Both 
neutrophil CD11b and monocytes CD11b levels fell after 30 minutes of venous hypertension. 
The expression of L-selectin also fell but soluble plasma L-selectin levels increased during 
venous hypertension suggesting adhesion of these molecules to the endothelium (Saharay et 
al. 1997). This study suggests there in leukocyte interaction with the endothelium in patients 
with venous disease and that this could progress to inflammation.  
Powell et al took 2 samples of blood, one from the distal leg vein and the other from 
the antecubital fossa, in patients with varying forms of CVD and also healthy control group. 
They found that patients with CVD had increased percentages of both platelet-monocyte 
aggregates and platelet-neutrophil aggregates throughout the circulation when compared to 
the healthy control group. They concluded that the presence of more of these aggregates and 
the increased propensity to form aggregates in the presence of platelet agonists in all classes 
of CVD suggests an underlying state of platelet activation and increased reactivity that is 
independent of the presence of ulceration. They also found an increase in the expression of 
monocyte CD11b throughout the circulation in all classes of CVD that suggests that although 
systemic monocyte activation occurs in CVD, its presence is independent of the presence of 
ulceration as well (Powell et al. 1999). 
 There is increasing evidence that suggest that inflammation plays a key role in 
modulating MMP expression in systemic vessels. For example, in atherosclerosis MMP co-
localise with macrophages within atherosclerotic plaques, and cytokines like TNF-α, that 
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induce production of MMP, may be involved in initiating a cascade of events leading to 
plaque rupture and occlusion. In addition, mechanical injury to the wall of a blood vessel in 
animal models also induces MMP (Thakker-Varia et al. 1998). 
1.5.3.5 Cytokines And Their Role In Varicose Vein Disease 
Cytokines (Greek cyto-, cell; and -kinos, movement) are a category of signalling 
molecules that are used extensively in cellular communication. They are proteins, peptides, or 
glycoproteins. Cytokines are small secreted proteins which mediate and regulate immunity, 
inflammation and haematopoiesis. They are generally produced de novo in response to an 
immune stimulus, usually act over short distances, have a short half life and work at very low 
concentrations. Responses to cytokines include increasing or decreasing expression of 
membrane proteins, proliferation and secretion of effector molecules. 
Badier-Commander et al compared levels of transforming growth factor (TGF) β, 
fibroblast growth factor (FGF)-2 and vascular endothelial growth factor (VEGF) in control 
and varicose veins by a combined histological, immunohistochemical, and biochemical 
approach. This study found that both TGFβ1 and FGF-2 were present in control veins and 
also varicose veins, although they were more abundant in the latter. There was no significant 
difference in VEGF between varicose vein and normal veins. There were also no 
inflammatory cells present, suggesting that an inflammatory mechanism is unlikely to account 
for cytokine modulation (Badier-Commander et al. 2001). Murphy et al also confirmed the 
presence of cytokines in CVD and varicose vein disease in serum samples taken from the leg 
and measuring the level of TNF-α and VEGF. Both groups of patients were found to have 
elevated levels of these cytokines. The CVD group were then managed with 4-layer graduated 
compression to attempt to reverse the venous hypertension and then had regular follow up to 
further assess cytokine levels. It was found that there was a reduction in both cytokines to 
below control values with treatment (Murphy et al. 2002). Hollingsworth et al attempted to 
induce blood stasis by application of a tourniquet for 10 minutes on both a control group and 
also a group with primary varicose veins to measure change in levels of VEGF. Baseline 
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levels of VEGF were similar in both groups as well as between arm and foot samples. 
However after induction of blood stasis the control group showed a clear increase in the mean 
levels of VEGF. In contrast, the varicose vein group, showed no significant alteration in 
VEGF suggesting the tourniquet was insufficient to stimulate the response required to 
produce VEGF (Hollingsworth et al. 2001). Signorelli et al also induced venous stasis in 
patients with varicose veins and patients with non-varicose veins using the tourniquet method. 
They reported an increase in TNF-α, IL-1β and IL-6 in varicose vein patients in comparison 
to non-varicose vein patients and this became even more marked when induced stasis had 
been performed (Signorelli et al. 2000). 
MMP and TIMP have been shown to be stimulated by inflammatory cytokines. 
Among the agents that induce MMP and TIMP production are the inflammatory cytokines 
TNF-α and IL-1β (Borden and Heller 1997). This is especially true for TIMP-1 although 
TNF-α appears to have little effect on MMP-2. It is thought that various other cytokines and 
soluble factors such as angiotensin II, PMA and retinoids may also play a key role. There is 
presently no data specific to varicose veins to support this. 
1.5.4 BLOOD STASIS AND HYPOXIA AS A CAUSE FOR VARICOSE VEINS 
1.5.4.1 Blood Stasis As A Cause For Varicose Vein Disease 
The lack of the “calf muscle pump” action, as seen in varicose veins, contributes to a 
lack of venous return. This in turn may lead to increased venous filling and subsequently a 
rise in intraluminal venous pressure within the veins of the legs. The resultant blood stasis, 
relative hypoxia, reduction in pH (Cheatle et al. 1998) and associated increase in oxidative 
metabolites may all contribute to vein wall damage. 
It is thought standing, alone, can promote blood stasis in the lower limbs and that 
such stasis will promote ischemia decreasing the oxygen availability to the tissues. Gaylarde 
et al has supported this hypothesis by showing there is a link between stasis and hypoxia, 
reporting improvement in skin blood flow by application of external compression stockings in 
standing subjects thus preventing microcirculatory stasis secondary to venous hypertension 
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(Gaylarde et al. 1993). Alterations in the microcirculation in CVI are thought to be due to a 
mixture of venous stasis, high capillary pressure and anoxic tissue. Matic et al has reported 
that the partial pressure of oxygen is higher in ulcerated limbs than those without ulceration 
which they suggest is due to blood passing directly from arterioles to venules over arterio-
venous temperature-regulating shunts in the dermis (Matic et al. 2000). However another 
study found significant skin hypoxia in patients with venous disease and skin ulcerations 
(Clyne et al. 1985). Jacob et al studied the relationship between blood stasis and MMP-9. 
Blood was taken at rest (supine) from varicose vein and brachial vein and then again after 30 
minutes of stasis. After 30 minutes of blood stasis the partial pressure of oxygen decreased 
although thrombomodulin, vWF, VEGF and MMP-2 were not modified. However, there were 
significant increases in endothelial intercellular adhesion molecule-1, vascular cell adhesion 
molecule-1 and angiotensin converting enzyme. Leukocyte markers lactoferrin, 
myeloperoxidase and IL-8 were not modified whereas L-selectin shed from leukocytes 
increased, as did pro-MMP-9 (Jacob et al. 2002). This study also shows that MMP are 
important proteolytic enzymes in patients with CVD and are involved in the interaction 
occurring between leukocytes and the endothelium in varicose veins.  
Animal studies have helped illustrate the role of MMP as well as valve and venous 
wall changes. A feasible in vivo model appears to be a rat with induced venous hypertension 
due to the formation of a femoral arteriovenous fistula and the control as the contralateral 
femoral vein in the same rat. Studies have shown that the formation of a fistula induces 
significant venous hypertension in femoral vein leading to dilatation and progressive reflux. 
The veins become dilated with subsequent valve damage including reduction in the height and 
width of the valve and fibrosis (Takase et al. 2004; Pascarella et al. 2005). One study noted 
significant inflammatory response with an infiltration of leukocytes into the entire vein wall 
with an increase in P-selectin and intercellular adhesion molecules. Interestingly this group 
reported an increase in the number of apoptotic cells found in the vein wall and valves which 
is contradictory to previous findings by others. They also found no differences in MMP-2 or 
MMP-9 at 3 weeks (Takase et al. 2004). Another study with an identical model noted 
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complete valve obliteration and an increase in both MMP-2 and MMP-9 at day 21 and 42 
(Pascarella et al. 2005).  
1.5.4.2 Hypoxia As A Cause For Varicose Vein Disease 
Although hypoxia has been suggested as being involved in varicose vein disease, 
there has been very little work concentrating on the possibility and perhaps subsequent effects 
of hypoxia in either the venous macrocirculation or microcirculation of the leg, although there 
has been some investigation of the role of hypoxia in severe venous disease resulting in 
ulceration. 
Hypoxia has been sub-divided by time span. Acute hypoxia activates endothelial cells 
to release inflammatory mediators and growth factors, which together with platelet-activating 
factor promote neutrophil adherence to the endothelium. Chronic hypoxia is thought to 
increase the expression of specific genes that encode for cytokines as well as growth factors 
e.g. VEGF, platelet-derived growth factor. These genes are modified by transcription factors, 
the most important being hypoxia inducible factor (HIF) (Hollingsworth et al. 2001). The 
proteins of these factors are activated in response to periods of hypoxia-induced physiological 
stress (a decrease in the concentration of molecular oxygen) and this adaptive pathway 
regulates changes in gene expression that then mediates adaptation and survival of the cells. 
HIF transcription factors are a complex of two (α and β) sub-units: the hypoxia 
regulated α subunit and the oxygen insensitive β subunit. Under normal oxygen conditions 
the α subunit has a short half life and is rapidly degraded by hydroxylation  of proline 
residues by prolyl 4-hydroxylases (PHD), which requires oxygen as a co-substrate. This 
allows binding of the von Hippel-Lindau (VHL) ubiquitin ligase complex, which targets HIF-
α for proteasomal destruction. This means that no HIF protein accumulates. However, when 
the conditions change and become hypoxic the degradation of the a subunit is blocked and it 
therefore accumulates within the nucleus where it binds to the HIF-1β and this complex 
recognises and binds to HIF-responsive elements (HRE’s) in the promoter or enhancer 
regions of various hypoxia-responsive target genes, which include VEGF (Figure 1.5).  
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Figure 1.5 Regulation of HIF-1 transcription factor 
In normoxia, HIF-1α is modified by HIF-prolyl hydroxylases, triggering HIF-1α recognition by pVHL 
and subsequent degradation. Hypoxia blocks this  mechanism allowing HIF-1α to accumulate and bind 
to p300 promoting the transcription of HIF-1 target genes 
 
 
 
 
 
 
 
 
 
In the context of varicose vein development, there is no clear evidence of how the 
initial insult of hypoxia could be brought about. Possibilities include: 1) blood stasis causing 
macrocirulatory ischemia damaging the endothelial cells of the intima, 2) hypoxia to the 
endothelial wall caused by insufficient supply by the vasa vasorum in the adventitia and 3) 
tissue hypoxia due to alterations in the microcirculation (Nicolaides et al. 2008).  
Taccoen et al measured oxygen tension in vivo of 31 varicose veins and 7 normal 
veins using a computerized polarographic system Kimoc 6650. This allowed blood samples to 
be taken by a needle probe in a microdriven stepwise fashion. The oxygen tension profile was 
similar in both groups of patients. Oxygenation of the outer two thirds of the venous wall is 
provided by vasa vasorum. The average minimum values in the media was significantly 
reduced in varicose veins compared to non-varicose veins which would indicate that there is 
good reason to believe that there is a deficiency in the oxygen supply in varicose veins and 
that potentially the vasa vasorum may be affected as suggested above (Taccoen et al. 1996). 
As explained above, VHL plays an important role in the regulation of HIF. VHL has 
been linked to the regulation of cell cycle cessation (G(0)) and to the control of expression of 
various mRNAs via HIFs e.g. VEGF. Loss of function of the VHL tumour suppression gene 
occurs in familial and most sporadic renal cell carcinomas (RCC). Koochekpour et al 
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compared VHL-positive RCC cells with VHL-negative RCC cells. They found that the VHL-
negative cells expressed reduced levels of TIMP-2 relative to VHL-positive cells. This would 
indicate the VHL plays a role in the regulation of TIMP-2 (Koochekpour et al. 1999) and 
given their similarity, potentially may be involved in the regulation of other MMP and TIMP. 
There is another genetic condition that also involves the VHL gene. Chuvash polycythaemia 
is an autosomal recessive disorder with increased serum erythropoietin levels and 
haemoglobin concentrations in normoxia that is endemic in Chuvashia. It is characterised by 
homozygous mutation (598C>T) of the VHL gene resulting in elevated normoxic levels of 
HIF-1α. Because of this germline mutation in the VHL gene it is thought that homozygotes 
for this mutation may develop certain vascular tumours similar to those associated with 
classic vHL syndrome. Gordeuk et al performed a matched cohort study and showed that 
VHL 598C>T homozygosity is associated with varicose veins, lower blood pressures, 
elevated serum VEGF, and premature mortality related to cerebrovascular events and 
peripheral thrombosis (Gordeuk et al. 2004). 
Following on from the evidence written above, research has shown that hypoxia may 
regulate MMP and their inhibitors. HIFs are the transcription factors that mediate the adaptive 
response to hypoxia. As previously described above, in order to prevent the accumulation of 
HIF protein, VHL ubiquitin ligase binds to the prolyl hydroxylated HIF (the alpha subunit of 
either HIF-1 or HIF-2) complex, and promotes destruction via the proteasome pathway. 
Petrella et al described a connection between the loss of the VHL tumour suppressor function 
and the up-regulation of MT1-MMP gene and protein expression, which was medicated by 
HIF-2. They also identified a functional HIF-binding site in the proximal promoter of MT1-
MMP. This suggests that as HIF accumulates, MT1-MMP gene expression and protein 
production is increased (Petrella et al. 2005). There have also been reports of an increase in 
MMP-2 mRNA expression and protein in endothelial cells (Ben-Yosef et al. 2002). MMP-2 is 
secreted as a pro-enzyme and undergoes activation through interaction with MT1-MMP and 
TIMP-2 forming a ternary complex. In another study using endothelial cells, hypoxia was 
shown to increase both MT1-MMP and MMP-2 mRNA thereby up-regulating MMP-2 
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activation (Ottino et al. 2004). This finding was also supported by Chen et al who exposed rat 
hepatic stellate cells to hypoxia and noted that the expression of MMP-2 was enhanced (Chen 
et al. 2001) . However there is one study by Ye et al that reports down regulation of protein 
content and activity of MMP-2, in response to hypoxia, in porcine pulmonary artery 
endothelial cells (Ye et al. 2005). Similarly, TIMP have also been reported to be regulated by 
hypoxia. There are conflicting reports in one study endothelial cells exposed to hypoxia 
suppressed TIMP-2 mRNA (Ben-Yosef et al. 2002) but in another study hypoxic endothelial 
cells increased TIMP-2 mRNA expression (Ottino et al. 2004). Another study analysing 
VHL-negative RCC cells (which reproduce the hypoxic milieu since HIF degradation is 
prevented) expressed reduced levels of both TIMP-1 and TIMP-2 when compared to VHL-
positive cells. This implies that VHL is involved in the regulation of these molecules. 
Interestingly when analysing MMP they found that MMP-2 and MMP-9 elevated 
(Koochekpour et al. 1999). There is very little data on HIFs and TIMP-3. Yamaguchi et al 
looked at the effect of hypoxia alone and also the effect of hypoxia together with IL-1β 
stimulated temporomandibular joint disc cells. Together hypoxia and IL-1β caused a 
significant decrease in TIMP-3. In the same cells they also found a significant increase in 
MMP-2 in group that were only exposed to hypoxia (Yamaguchi et al. 2005). 
There is increasing evidence that HIF-1 may play a role in immune reactions 
suggesting an association with cytokines. Scharte et al investigated the effects of cytokines on 
HIF-1 in the presence of normoxia (21% oxygen) and hypoxia (1% oxygen) using human 
transformed intestinal cells. They found that IL-4 significantly increased HIF-1 protein levels 
during hypoxic episodes and not in normoxia. There was no upregulation of HIF-1 DNA-
binding activity or HIF-1 dependent gene expression. IL-10 had no effects on HIF-1 protein 
levels (Scharte et al. 2006).This had been shown by Cramer et al who examined the 
inflammatory response in conditional HIF-1α knockout mice (myeloid-specific knock-
outs). They proved that HIF-1α is essential for the chief cellular agents of innate immunity - 
myeloid cell infiltration and activation (Cramer et al. 2003). This would strengthen the 
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suggestion of a link between cytokines and HIFs. It is known that VEGF is a downstream 
target gene of HIF-1α. Li et al investigated the expression of HIF-1α and VEGF in 
pulmonary arteries of rats with hypoxia induced pulmonary hypertension. They found that 
HIF-1α and VEGF were both involved in the pathogenesis of hypoxia induced hypertension 
in rats. HIF-1α tended to peak at 7 days exposure to hypoxia and remained elevated until day 
14. VEGF protein however peaked later at day 14 (Li and Dai 2004). Ozaki et al also showed 
an increase of HIF-1α expression when exposed to hypoxia and a corresponding increase of 
VEGF in ischemic retinal vessels (Ozaki et al. 1999). In contrast, presently there is little 
literature to suggest a link between HIFs and TNF-α. In fact it has been commented that 
hypoxia-induced TNF-α expression occurs via hypoxia-activated signals independent to those 
of the HIF-1 pathway (Li et al. 2005). Hellwig-Burgel et al suggest that inflammatory 
cytokines, like TNF-α and IL-1β, actually stimulate HIF-1-dependent gene expression 
themselves, even in normoxic cells. It is thought that both hypoxic activation and the 
cytokine-induced activation of HIF-1, use signalling pathways that involve 
phosphatidylinositol-3-kinase and mitogen-activated protein kinase (Hellwig-Burgel et al. 
2005). This implies that the HIF-1 pathway is still used but a reduced oxygen concentration 
does not have to be present in order for the pathway to be activated. Zhang et al commented 
on the fact the IL-1β shares common features with other known HIF-1α regulated genes. In 
fact IL-1β genes carry multiple binding sites in their promoter regions. They report that there 
is transcriptional activation of IL-1β in astrocytes exposed to hypoxia and that this occurs 
through the HIF-1 pathway (Zhang et al. 2006). It has also been shown in desferrioxamine-
stimulated cochlear auditory cell lines that IL-6, another inflammatory cytokine, production 
can be increased in hypoxic conditions and this is associated with the activation of HIF-1 and 
MAPK (Jeong et al. 2005). 
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1.6 HYPOTHESIS AND OBJECTIVES 
To summarise, varicose veins are a common problem that for a multitude of reasons 
often require surgical intervention. Their aetiology is poorly understood. Literature is limited 
and inconsistent. There are a number of theories as to whether the pathological process occurs 
at the valves or the vein wall, whether it is inflammatory or genetic and if and how hypoxia 
may be involved. 
My hypothesis in this study was that varicose veins result from vein wall remodelling 
due to alternation in the MMP/TIMP balance as a consequence of stimulation by 
inflammatory cytokines and/or hypoxia.  
In order to explore the above, my objectives were: 
1) to determine the relationship between inflammatory cytokine expression and 
matrix-degrading MMP and their inhibitors in varicose veins 
2) to investigate whether hypoxia is a feature of varicose veins and leads to 
alterations in MMP 
3) To assess the effect of hypoxia on human saphenous endothelial cell 
expression of MMP. 
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2 MATERIALS AND METHODS 
 
2.1 PATIENT SELECTION AND TISSUE SAMPLING 
2.1.1 PATIENT SAMPLING 
The patients were assessed in the Outpatient Department at Charing Cross Hospital in 
a Consultant led clinic for varicose veins (VV), to determine whether or not they required 
surgery for definitive management of their condition. Patients who were undergoing 
operations for primary varicose vein of the greater saphenous system of the superficial veins 
were chosen for the study. Those undergoing operation for disease in the short saphenous 
system and/or recurrent varicose vein disease were excluded. The patients then attended either 
as a day case or as an inpatient and were informed of the study and consent obtained. 
Assurance was provided regarding data protection and tissue disposal.  
A full medical history, including drug history was obtained from the patient. The 
ideal criteria for this study would be to exclude patients with various co-morbidities such as a 
history of DVT, diabetes, rheumatoid arthritis, connective tissue disorders, known 
arteriopaths and cancers. This is because these conditions affect the structure of the vein wall. 
For example DVT causes an early increase in neutrophil infiltration in vein walls which is 
associated with inflammation and is likely to contribute to vein wall injury (Downing et al. 
1996). Connective tissue disorders are known to affect the quality and quantity of collagen 
and elastin present in the dermis (Holbrook and Byers 1982). Collagen and elastin are also 
abundant in the venous wall so patients who have a connective tissue disorder are likely to 
have similar alterations in their vein walls. There is also evidence that malignancy may be 
associated with changes in proteinase expression, either because of the potential cause, like a 
virus (Katori et al. 2006), or due to the medications used to treat them (Iovieno et al. 2009) 
Other conditions will also require the patient to take medication, for example arteriopaths and 
patients receiving statins, which may influence MMP (Turner et al. 2005; Wilson et al. 2005). 
However, these criteria could not be met in the veins from other sources group of patients, as 
MD (Res) Thesis Beverley Saunders 
Chapter 2 
 50
the subjects were most likely to be arteriopaths or patients that have chronic renal failure. 
Both of these conditions involve the patients regularly taking a number of medications and 
predisposing the patients to a number of co-morbidities such as DVT etc. Therefore, these 
patients could not be excluded, otherwise a comparative group of sufficient size would not 
have been available. A very small number of patients in the varicose vein group also 
experienced some of the factors that ideally would be excluded from the study. The severity 
of the pathology that they displayed was very minor with respect to the veins from other 
sources group, as open varicose vein surgery is generally only performed on healthy 
individuals due to the risk of anaesthesia. I have therefore included these patients in this 
study. Throughout analysis, any changes noted in MMP/TIMP expression have been 
considered with caution. 
Clinical examination was carried out, and all patients who had varicose vein 
operations had duplex scans to assess their lower limbs pre-operatively. A duplex scan is a 
combination of ultrasound and Doppler signals. Ultrasound allows visualisation of the veins 
while Doppler signals help to identify the direction of the blood flow. This aids, together with 
the clinical picture, confirmation of the site or sites of the disease showing whether or not 
valves are competent or incompetent. 
Veins from other sources (VOS) were obtained from patients undergoing arterial 
bypass, carotid endarterectomy operations or arterio-venous fistula formation at the Charing 
Cross Vascular Surgical Department and used for comparison (see Sections 2.1.5, 2.1.6 and 
2.1.7 below). 
Pre-operatively, full written consent was obtained. This usually occurred on the day 
of the operation. The patient was informed what kind of tissue and the amount that would be 
taken, and it was carefully explained that the tissue would otherwise have been discarded. The 
informed consent was obtained by the doctor who was to perform the operation. Once the 
specimen had been taken in the operating theatre it underwent collection and anonymisation 
which was performed by a dedicated member of staff in liaison with the tissue bank at 
Charing Cross Hospital. Once the experiments had been completed, anonymity was reversed 
MD (Res) Thesis Beverley Saunders 
Chapter 2 
 51
and the clinical case notes of the patients recalled from the medical records department. They 
then underwent systematic review looking at the following: Gender, Age, Race, Parity, BMI, 
co-morbidities and medications. 
2.1.2 DEMOGRAPHICS OF THE STUDIED POPULATION 
The studied population were taken from patients that underwent operation under the 
guidance of Professor Alun H. Davies, Consultant Vascular Surgeon, in Charing Cross 
Hospital. A total of 29 patients were enrolled and included those undergoing varicose vein 
surgery, leg bypass operations from whom GSV segments were harvested, Carotid 
Endartarectomy from whom facial vein was harvested and fistula formation from whom arm 
vein was harvested. 
There were 7 males (47%) in the varicose vein group and also 7 males (50%) in the 
veins from other sources group, compared with 8 females (53%) in the varicose vein group 
and 7 females (50%) in the veins from other sources group (no significant difference using 
Fishers exact test) (Figure 2.1).  
 
 
Figure 2.1 Gender distribution in the studied population 
Bar chart to represent 29 patients who underwent surgery. 8 females and 7 males had varicose vein 
surgery and 7 females and 7 males underwent an alternative operation in which VOS were retrieved 
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The mean age of the varicose vein patients was 41.13 years (range 24-61), while the 
patients who supplied veins from other sources had an average age of 69.93 (range 52-93). 
This difference was highly significant using an unpaired t-test (p=<0.0001) (Figure 2.2) 
 
Figure 2.2 Age of the studied population 
Scatter plot to show the ages of the 29 patients who underwent surgery divided by the type of 
operation. Data are shown with mean values. 
 
 
 
A total of 33% of the varicose vein group were smokers, compared with 71% in the 
veins from other sources. I included patients that had claimed to have recently given up 
smoking, i.e. the last 6 months, and also those that had given up in the last 5 years that 
smoked over 20 cigarettes a day (Figure 2.3). 
When comparing the 2 groups, 27% of the varicose vein group suffered with 
hypertension, whereas it affected 100% of the patients in the veins from other sources group, 
as might be expected. The patients in veins from other sources group, 64 % had some form of 
ischaemic cardiac compromise and 43% had peripheral vascular disease. There were no 
arteriopaths in the varicose vein group. 1 patient from each group had experienced a DVT. 
Although there was a larger number of patients taking Aspirin, Steroids and Statins in 
the veins from other sources group there was still a small proportion of patients on regular 
aspirin and inhaled sreroids in the varicose vein group. 
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Figure 2.3 Comparison of the co-morbidities and other characteristics of patients included 
in the study 
Bar chart to show the number of patients with co-morbidities amongst the 2 specimen groups. 
 
 
 
2.1.3 ETHICAL APPROVAL 
Ethical approval has been granted for the project (Riverside Research Ethics 
Committee: RREC3092: The Role Of Matrix Metalloproteases And Their Inhibitors In The 
Development Of Varicose Veins; RREC3199: Pro-Inflammatory And Pro-Thrombotic Profile 
Of Aneurismal And Occlusive Atherosclerotic Disease – A Novel Ex Vivo Approach; 
RREC2989: An Investigation Into Factors Influencing Atheromatous Plaque Instability; REC 
06/Q0407/27: Arteriovenous Fistulae: Factors Predicting Outcome). All the specimens were 
anonymised according to the rules set out in the Human Tissue Bill (2004). 
2.1.4 OPERATION FOR VARICOSE VEINS AND SPECIMEN COLLECTION 
The procedure commonly performed for this type of surgery is known as “High tie of 
the GSV and multiple avulsions” or traditionally Trendelenburg’s Operation. This is usually 
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performed under general anaesthesia. It involves a 5cm oblique groin incision, just below and 
parallel to the inguinal ligament in the groin crease, to expose the saphenofemoral junction. 
Once the saphenofemoral junction has been dissected, along with its tributaries, the tributaries 
must all be ligated. The junction is then ligated flush with the deep vein and the length of the 
vein then stripped to below the knee using a plastic stripper. Skin wounds were closed using 
absorbable sutures. The operation is concluded by avulsions. Avulsions are the removal of 
small prominent veins under the skin and are removed by small incisions placed directly over 
them and pulled out using a vein hook. Compression bandaging, to avoid haematoma 
formation, is applied at the end of the operation. The recorded blood loss for this operation is 
around 500ml; it rarely requires an overnight stay and patients can return to their normal work 
within a week, or less depending on their age and co-morbidities.  
The tissue for the research was obtained at 2 stages. Initially after the proximal end of 
the vein was flush ligated with the deep vein, a segment of 2-3cm was excised from the main 
vein segment. This specimen would usually have been discarded after the operation. At the 
stage when the vein was stripped, a piece of similar dimension was also excised from the 
distal end, around the knee (Figure 2.4). Comparison of these two different anatomical sites is 
important as it has been shown that ambulatory venous pressure of the lower extremities 
differs between proximal and distal segments (Neglen and Raju 2000). Each of the specimens 
were marked as “proximal” and “distal”. The specimens were retrieved by a designated tissue 
collector in accordance with the Human Tissue Act (2004). Specimens were then snap frozen 
in liquid nitrogen.  
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Figure 2.4  Lower limb showing the venous system and the site of vein retrieval during 
varicose vein surgery 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.5 COLLECTION OF GREATER SAPHENOUS VEIN TISSUE FROM BYPASS OPERATIONS 
These patients have experienced a blockage of the main arteries in the legs. 
Occasionally it is possible to unblock these arteries using a balloon in a procedure called 
angioplasty. However when this is not possible, in order to improve the blood flow to the 
foot, these patients would require an operation called a bypass. This involves bypassing the 
blockage by either attaching a vein, taken from the same patient, or a piece of artificial 
material, PTFE or Dacron. Vein bypass is considered superior to prosthetic grafts as they are 
durable with longer patency rates. Veins are preferred to be taken from the GSV; however if 
for some reason these are not available or suitable, then an arm vein can be used (see Section 
2.1.7 below). This procedure needs a preoperative Duplex assessment in order to assess to 
suitability of vein. During this scan the course of the vein was marked on the skin surface 
with indelible ink pen for easy salvage and placement of incision. This also helps in ruling out 
the presence of varicose veins as using a varicose vein for bypass can result in early failure 
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and aneurysmal dilatation of the bypass (Soury et al. 1999). At operation a skin incision was 
made along this marking and the vein dissected out. The vein was then reversed so that the 
existing valves do not prevent blood from flowing down the leg and sutured to the arteries in 
order to re-establish blood flow. If there was any vein left surplus to the requirement for the 
procedure, this was used for research. These segments were treated in exactly the same way 
as varicose veins, retrieved by the designated tissue collector, snap frozen and stored for 
experiments in the -80°C freezer. 
2.1.6 COLLECTION OF NECK VEINS 
The brain relies on oxygen supplied in blood from the heart via the carotid arteries. 
These arteries can become blocked by atheromatous plaques which therefore reduce the blood 
flow to the brain. In order to re-establish this flow and reduce the potential threat of small bits 
of plaque breaking off and travelling up to the brain causing a stroke, a carotid 
endarterectomy can be performed. This involves coring the narrowing plaques out from the 
artery. This operation is prophylactic, in that it will not improve the symptoms that have 
occurred due to a previous stroke. 
At operation, an incision was placed along the side of the neck and tissue dissected 
along the artery to gain access to them above and below the blockage. The artery needs to be 
completely exposed in order for success. This complete exposure is often hindered by the 
facial or jugular vein which travels across part of the artery and hence one of the important 
steps of the operation is to ligate and separate them. These excised segments were used for 
research as neck veins, they were immediately retrieved by the designated tissue collector, 
snap frozen and stored for experiments in the -80°C freezer. Neck veins are very tiny and in 
order to be able to extract RNA from them I had to accumulate four specimens and treat it as 
one. The samples were amalgamated at the time of pulverisation.  
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2.1.7 COLLECTION OF ARM VEINS 
Arm veins were collected from two types of patients. The first were patients already 
described in Section 2.1.5, who underwent arterial surgery on the lower limb using arm veins 
as grafts, and the second are chronic renal failure patients requiring haemodialysis. 
Chronic renal failure is a common condition which leads to gradual and complete 
shutdown of the kidneys. The kidney has the role of filtering toxic materials out of the body. 
When it shuts down dialysis helps to support bodily functions. There are 2 types of dialysis, 
peritoneal and haemodialysis. Peritoneal dialysis depends on fluid inserted in to the 
abdominal cavity to remove the toxic materials, whilst haemodialysis involves the removal of 
blood from a vein; filtering it outside the body in a machine called a dialyser and re-infusing 
it back in to the body through the arm vein. This is a cyclical process that takes 3-4 hours. 
One of the crucial requirements for this procedure is access to a vein with a good blood flow. 
This was done by the formation of “Cimino” fistulas which are a communication between an 
artery and the vein in an accessible part of the body – usually the arm. The arterial component 
makes sure that there is good blood flow whilst the veins, which are superficial, give easy 
access. A classic example is a radio-cephalic fistula which is formed between the radial artery 
and the cephalic vein. Patients who require fistula formation were referred from different 
hospitals to Charing Cross Vascular Surgery Department. The patients were seen in the clinic 
and underwent pre-operative assessment in the form of Duplex scan in order to assess 
suitability of the vein depending on calibre and accessibility and at the same time underwent 
marking.  
The surgery was mostly under local anaesthetic. The vein segment was dissected out 
followed by the artery to which it was then connected in order to form the fistula. It was a 
usual precaution to dissect out extra length on the vein segment in case the previous 
determined length was not sufficient to approximate the vein to the artery to form the fistula. 
If there was any excess length of vein segment after formation of fistula it was used for 
research purposes. This was treated as in the cases of the other veins, retrieved by the 
designated tissue collector, snap frozen and stored for experiments in the -80°C freezer. 
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2.2 QUANTITATION OF mRNA FOR GENES OF INTEREST 
2.2.1 EXTRACTION OF MRNA FROM VARICOSE VEIN TISSUE AND VEINS FROM OTHER 
SOURCES 
The following section describes isolation of total RNA from tissue, which ensures 
that the integrity of RNA is maintained. The technique utilised varicose vein tissue, either 
proximal or distal, or veins from other sources, which were rapidly snap frozen (liquid 
nitrogen at -196°C and then stored at -80°C). 
The vein tissue was pulverised to a fine powder using a mechanised pestle and mortar 
cooled with liquid nitrogen in order to keep the tissue frozen, and then transferred into bijou 
bottles and kept frozen. The RNA had to be preserved so pulverisation had to be fast and 
thorough, and it was imperative to keep the tissue frozen until it came in contact with the 
denaturant. Prior to homogenisation, the tissue was weighed and 1ml TRIZOL® Reagent 
(Invitrogen Life Technologies, Paisley, UK) per 100mg tissue was added. TRIZOL® is a 
mono-phasic solution of phenol and guanidine isothiocyanate that contains a combination of 
denaturants and RNAase inhibitors. During sample homogenization, TRIZOL® reagent 
maintains the integrity of the RNA, while disrupting cells and dissolving cell components. 
Homogenisation was carried out until tissue slurry was apparent. For phase separation, the 
slurry was centrifuged (12,000 x g, 10 minutes), the supernatant removed, leaving pelleted 
debris which was discarded. 200μl chloroform (VWR International Ltd, Lutterworth, 
Leicestershire, UK) was added to the supernatant and left to stand for 2-3 minutes, prior to 
centrifugation (12,000 x g, 15 minutes at 4°C). This allowed separation of the solution into an 
aqueous phase and an organic phase. RNA remains exclusively in the aqueous phase. 
RNA was precipitated by pipetting off the clear aqueous phase and 550μl acid phenol 
chloroform added, followed by vortexing for 1 minute and centrifugation (12,000 x g, 5 
minutes at 4°C). 500μl propan-2-ol (VWR International Ltd, Lutterworth, Leicestershire, UK) 
was then added to the aqueous phase, inverted and left to stand for 10 minutes before finally 
centrifuging (12,000 x g, 10 minutes at 4°C). The RNA pellet was washed by the addition of 
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1ml 75% ethanol, which was removed by centrifugation (12,000 x g, 5 minutes). After air 
drying for 5 minutes, the pellet was re-suspended in 50μl of diethylpyrocarbonate (DEPC, an 
irreversible RNase inhibitor)-treated water (QIAGEN, GmbH, Germany). When the pellet 
was difficult to re-suspend this step was aided by heating the pellet to 55°C. 1μl of RNasin (a 
broad spectrum RNase inhibitor; Promega, Southampton, UK), 5μl of 10xDNase buffer and 
2μl of turbo DNase (to remove trace quantities of DNA; Ambion, Huntingdon, 
Cambridgeshire, UK) was added. This was then incubated at 37°C for 30 minutes before a 
further 1μl of turbo DNase was added. The mixture was incubated at 37°C for a further 30 
minutes. 10μl of the DNase inactivation agent was then added to stop further reaction and 
mixed by vortex before being incubated at room temperature for 2 minutes. The final mixture 
was centrifuged at 10,000 x g for 2 minutes and the RNA was transferred to a fresh eppendorf 
tube. 
The extracted RNA was run on a gel to confirm the presence of RNA (as 18S and 28S 
ribosomal RNA bands) as shown below in Figure 2.5 (see Section 2.2.5 for gel 
electrophoresis methodology). 
 
 
Figure 2.5 Gel electrophoresis confirming the presence of mRNA 
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Subsequently, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) PCR was 
carried out at this time point in order to confirm the absence of DNA in the sample. An 
example of the gel electrophoresis is shown in Figure 2.6 (for PCR and gel electrophoresis 
method please refer to Sections 2.2.3 and 2.2.5). 
 
Figure 2.6 Gel electrophoresis of GAPDH PCR confirming the absence of genomic DNA in 
RNA sample 
 
 
 
 
 
 
 
 
 
2.2.2 PREPARATION OF CDNA FROM MRNA – REVERSE TRANSCRIPTION 
Once the absence of DNA was confirmed in all the samples, the RNA was quantified 
by absorbance using a spectrophotometer, which measures absorption of light at 260nm. The 
spectrophotometer was allowed to warm up and the setting of DNA/RNA selected. The 
spectrophotometer was calibrated to zero using a cuvette of 70μl DEPC-treated water. For 
sample readings, 7μl of sample RNA was added to 63μl of DEPC-treated water and then 
transferred to the spectrophotometer machine in order to measure the A260. By using the 
calculation below it was possible to find of the amount of RNA in micrograms per millilitre: 
A260 reading x 40 x dilution factor (1:10) = μg/ml RNA 
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500ng of RNA in a volume of 11μl were added to 1μl of random primers (Invitrogen 
Life Technologies, Paisley, UK) to make a total volume of 12μl. Random primers, as opposed 
to specific primers, were used as they non-specifically transcribe all mRNA present within the 
reaction mix, thus, maximising the number of molecules that can be analysed from a small 
sample of RNA. This was incubated at 70°C for 10 minutes to denature the RNA. In order to 
keep the RNA single-stranded the sample was then placed immediately on ice for 5 minutes. 
Direct amplification of RNA is limited due to the inability of Taq polymerase to 
recognise RNA as a template. To overcome this, a retroviral reverse transcriptase (RT) 
enzyme was used to produce a complementary strand of DNA (cDNA) for the RNA template. 
Reverse transcription was carried out using Moloney murine leukaemia virus (MMLV) RT 
(Promega, Southampton, UK). This required the use of the following components added to 
each sample in the form of a master mix: 
- 4μl of 5x MMLV Reaction Buffer (Tris hydrochloride, potassium chloride 
and magnesium chloride, all essential for the reaction; Promega, 
Southampton, UK) 
- 1μl RNasin 40 Units/μl; to inhibit any RNA contamination in the cDNA 
(Promega, Southampton, UK) 
- 1μl dNTP; this adds the nucleotides required for the building of cDNA from 
RNA by reverse transcription and is a combination of dATP, dCTP, dGTP 
and dTTP (Promega, Southampton, UK) 
- 0.5μl of MMLV 200 Units/μl (RNAse H minus point mutant; Promega, 
Southampton, UK) 
- 1.5μl of water 
The samples, with the added mastermix, were incubated at 25°C for 10 minutes in 
order to allow the primers to anneal to the RNA. They then underwent 42°C for 60 minutes, 
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and incubation at 70°C for 15 minutes, for the reverse transcription reaction, before being 
placed on ice for 5 minutes. A summary of the complete reaction is shown in Table 2.1. 
 
 
Table 2.1 Summary of RT reaction using a thermocycler 
 
Temperature Time Process
70oC 10 mins
4oC 5 mins
25oC 10 mins Anneal Primers
42oC 60 mins
70oC 15 mins
4oC Forever
Denatures 
secondary structure 
of RNA
Reverse 
Transcription
Addition of Mastermix
 
 
1µl of the RT reaction was used in a GAPDH PCR in order to confirm the presence 
of cDNA, as described below. An example of the gel is shown in Figure 2.7. 
 
2.2.3 POLYMERASE CHAIN REACTION 
In order to investigate if the genes of interest were expressed in the venous samples, 
the cDNA was amplified using Polymerase Chain Reaction (PCR) using specific primers for 
the genes of interest and then electrophoresed on a Sybr Green agarose gel and visualised by 
an ultraviolet transilluminator in a Biodoc cabinet. 
A master mix was prepared using the components in Table 2.2 for the required 
number of samples, including a positive (cDNA prepared from RNA known to contain gene 
of interest) and negative control (only containing 24μl of mastermix). 24μl of the master mix 
was transferred in to the 200μl PCR tubes and subsequently 1μl of the appropriate cDNA then 
also added to the pre-marked tubes. 
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Table 2.2 Contents of PCR master mix 
PCR ready kit provided 10xPCR Buffer, MgCl2 and Taq ((Invitrogen Life Technologies, Paisley, UK). 
Primers (Eurofins MWG Operon, Germany) were sourced separately as was the dNTP (Promega, 
Southampton, UK) 
 
 
Concentration Final Amount (μl)
10 x PCR Buffer 
(Invitrogen Life 
Technologies)
10x 1x 2.5
dNTP (Promega, 
Southampton, UK)
10mM 200μM 0.5
Forward Primer 
(MWG)
12.5μM 0.25μM 0.5
Reverse Primer 
(MWG)
12.5μM 0.25μM 0.5
MgCl2 (Invitrogen 
Life Technologies)
50μM 1.5μM 0.75
Taq Polymerase 
(Invitrogen Life 
Technologies)
5 units/μl 0.5 units 0.1
Water 19.15
24μlTotal  
 
 
PCR is a three step process, referred to as a cycle, that is repeated a specified number 
of times in order to replicate DNA in vitro. The process takes place in a thermocycler; this 
controls and alternates temperatures for programmed periods of time for the appropriate 
number of PCR cycles – usually between 30-40 cycles. One cycle consists of the following 
stages: i) denaturation ii) annealing iii) extension. 
Denaturation by heat (94°C) separates the double stranded DNA into two single 
strands. This occurs as the hydrogen bonds that link the base pairs are weak and therefore 
break easily at high temperatures. The bonds between the deoxyribose and phosphates are 
strong covalent bonds and so remain intact. 
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The annealing process allows the primers specific to the gene of interest to bind. Two 
primers are included in the PCR (see Table 2.3 and Table 2.4 for reaction details); one for 
each of the single strands that was produced during the denaturation process. The primers 
flank the sequence of interest that is to be replicated. The annealing temperature is usually 
between 40-65°C. 
Extension starts once the primers are annealed the temperature raised to 72°C and the 
enzyme Taq DNA polymerase is used to replicate the DNA strands. Taq DNA polymerase is 
a recombinant thermostable DNA polymerase from the organism Thermus aquaticus and 
unlike normal polymerase enzymes is active at high temperatures. Taq recognises primers 
bound to single stranded DNA and polymerises the reverse component strand using DNA as a 
template. It does this by facilitating the binding and joining of the complementary nucleotides 
that are free in the solution (dNTPs). Extension always begins at the 3’ end of the primer and 
continues towards the 5’ end of the template DNA making a double strand out of each of the 
2 strands. Taq DNA polymerase synthesises exclusively the 3’-5’ direction. 
At the end of the cycle there are two new strands of DNA identical to that of the 
original target. The DNA polymerase does not recognise termination sequences and carries on 
until it falls off. The new strands have a beginning which is defined by the 5’ end of the 
primer, but the 3’ end is not precisely defined. As the number of cycles increases a strand 
with more defined length is formed and serves as a template for the newly synthesised 
sequence. The DNA strand that is produced from the template then has a precisely defined 
length that is limited at either end by the 5’ end of each of the two primers. These DNA 
strands are called an amplicon. After a few cycles DNA strands that correspond to the target 
sequence are present in larger numbers than the variable length sequences. 
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Table 2.3 PCR primers 
 
Gene of 
interest Primer
Gene product 
size
Fwd: atgaggtccaccaccctgtt
Rev: catggagaaggctggggctc
Fwd: ctctggagaaactgctgcc
Rev: tgtagatgctgccattgtcg
Fwd: caagtggtccgtgtgaagtatg
Rev: cgtcatcgtagttggctgtg
Fwd: gtcttcaaggagcgctggttctg
Rev: tagcccggttctaccttcag
Fwd: gagtgcaagatcacgcgcgctgcc
Rev: tgggagatccctaagtgctg
Fwd: gtaactgcaagatcaagtcctgc
Rev: cctcattctttctggcatgg
Fwd: cttgctgctctacctccacc
Rev: ctgcattcacatttgttgtgc
Fwd: ccatgttgtagaaaccctcaag
Rev: ctgagtcggtcacccttctc
Fwd: gagcaacaagtggtgttctcc
Rev: gacacaaattgcatggtgaag
Fwd: caattcgttctgaagagccc
Rev: ctgcgtccgtagtttccttc
Fwd: ttctctctagtctcacgagggg
Rev: accataacaaaaccatccaagg
Fwd: gctgacaaggagaagaaaagga
Rev:ttgagactcaggttctcacgaa
ARP
MMP-2
MT1-MMP
TIMP-2
TIMP-3
VEGF 354
357
347
587
HIF-1α
HIF-2α 443
TNF-α
458
GAPDH 671
378
496
488
548
IL-1β
IL-6
469
 
 
 
Table 2.4 PCR cycle 
Example of PCR reaction: where X is the annealing temperature that is determined by the primers’ 
melting point. 
 
Step Temperature Time Cycles
94oC 5 minutes
94oC 30 seconds
Annealing X 30 seconds
72oC 40 seconds
72oC 5 minutes
4oC forever
For 36 cycles
Denaturation
Extension
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 GAPDH PCR was used not only to confirm absence of DNA in RNA samples (Figure 
2.6), but also to confirm the presence of cDNA after reverse transcription in the vein samples 
at various stages of their processes (Figure 2.7). GAPDH catalyzes an important energy 
yielding step in carbohydrate metabolism – the reversible oxidative phosphorylation of 
glyceraldehydes-3-phosphate in the presence on inorganic phosphate and nicotinamide 
adenine dinucleotide (NAD). Since this is an essential process in energy production, all cells 
express the enzyme at a relatively constant rate and it is therefore termed a “housekeeping” 
gene, as it is consistently detected in cellular DNA.  
 
Figure 2.7 Gel electrophoresis of GAPDH PCR confirming the presence of cDNA following 
reverse transcription 
 
 
 
 
 
 
 
 
 
 
2.2.4 PRIMER VALIDATION 
Primer3 software (http://frodo.wi.mit.edu/) was used to design the primers which 
were synthesized by MWG Biotech AG, UK. A validation assay was performed to monitor 
the difference in amplification efficiency on both the housekeeping genes and the genes of 
interest prior to quantitative PCR analysis (Livak and Schmittgen 2001). All the primers were 
validated with a reaction efficiency of between 92%-108%. If values were outside this range 
then the primers were redesigned and validated again. 
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2.2.5 GEL ELECTROPHORESIS 
In order to visualise the products of the PCR, agarose gel electrophoresis was 
performed in order to separate the amplified DNA. This technique separates macromolecules 
that differ in size. By placing the molecules on an electric field they migrate to the positive 
pole. Agarose gels are advantageous as they are non-toxic and simple to make, as well as 
allowing a large range of separation. A 100ml 1.2% agarose gel (polysaccharide extract from 
seaweed) was prepared by mixing 1.2g agarose (Invitrogen Life Technologies, Paisley, UK) 
with 100ml of an electrophoresis buffer, 1xTAE (Tris-acetate-EDTA, containing 40mM Tris 
base, 20mM acetic acid and 1mM EDTA). 10μl of SYBR safe DNA gel stain, a fluorescent 
dye used to stain nucleic acids, (Invitrogen Life Technologies, Paisley, UK) was added 
(1:10000 dilution in DMSO). The mixture was heated for approximately 90 seconds in a 
microwave, or until all the agarose was fully dissolved in the TAE. The solution was left to 
cool slightly and then poured in to the casting tray with the appropriate combs in place in 
order to make wells to place the PCR products in. This was then left to solidify. The gels were 
then placed into the electrophoresis chamber and just covered with buffer, 1xTAE. 4μl of 
loading dye (50mg Bromophenol blue (VWR International Ltd, Lutterworth, Leicestershire, 
UK), 8mls water and 12mls glycerol (VWR International Ltd, Lutterworth, Leicestershire, 
UK) was added to each sample in the PCR tube. 1μg of 1Kb marker (Invitrogen Life 
Technologies, Paisley, UK) was loaded for size reference into the first lane. 29μl of mixed 
PCR product and loading dye was then pipetted into subsequent wells. The positive and 
negative leads were then attached. The power supply was switched on at 140 mV for 
approximately 30 minutes. Electronic connection is confirmed as bubbles can be observed 
from the electrodes. The distance the DNA migrated was monitored by observing the tracking 
dye. When adequate migration had occurred the power was switched off and the gel removed 
from the tank and placed on an ultraviolet transilluminator. Sybr Green dye binds double-
stranded DNA and fluoresces at ultraviolet wavelengths. This highlights whether or not the 
gene of interest is present in the samples and also confirms the molecular weight of the gene. 
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2.2.6 QUANTITATIVE PCR 
Real-time or quantitative PCR is a powerful and rapid technique for nucleic acid 
amplification in a reaction which continuously monitors changes in fluorescence during 
cycling within a PCR tube. Quantitative PCR is based on the detection of a fluorescent 
reporter molecule that increases as the PCR products accumulate with each cycle of 
amplification. Quantitative PCR exceeds the limitation of traditional end-point PCR methods 
by allowing either an absolute or relative quantification of PCR product at the end of each 
cycle. 
Sybr Green Jumpstart Taq Readymix (Sigma, St Louis, MO, USA) (excitation and 
emission maxima of 494nm and 521nm respectively) was used for quantitation. This 
contained SYBR Green I dye, Jumpstart Taq DNA polymerase antibody which prevents non-
specific DNA amplification), deoxynucleotides (dATP, dCTP, dGTP, dTTP), and reaction 
buffer made up of 20mM Tris-HCl (pH8.3), 100mM KCl and 7mM MgCl2. It exhibits little 
fluorescence when in solution but emits a strong signal when bound to double stranded DNA. 
As each cycle proceeds, more double stranded DNA is produced and therefore more 
fluorescence can be detected. Sybr Green is inexpensive, simple to use and sensitive. 
However it will bind to any double stranded DNA in the reaction, including primer-dimers 
and misprimed products, which can result in an overestimation of the target concentration. 
Thorough testing of the primers was done to ensure no primer dimer or non-specific products 
were produced. Specific primers for the genes of interest were used for quatitative PCR and 
the primer pairs were validated to ensure amplification efficiencies of housekeeping gene and 
gene of interest were equal (Livak and Schmittgen 2001). 
The Corbett robot (Robotics CAS-1200) was used to prepare the quantitative PCR 
reagents, as specified in Table 2.5 below, in order to minimise the pipetting errors due to the 
relative small reaction volume. Each sample was duplicated and placed into a 100μl 
eppendorf. Two non-template controls (NTC’s) were also pipetted using water for control. 
These values were helpful in identifying and excluding any vein samples with threshold cycle 
(CT value) values that were either equal or greater than those of the NTC’s. After preparation 
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the tubes were then transferred to the RotorGene 6000, a 72 closed-tube centrifugal thermal 
cycler designed by Corbett Research (Mortlake, Sydney, Australia) for analysis. 
 
Table 2.5 Quantitative PCR mastermix reagents 
Reagents Concentration Volume
SYBR Green 
Ready Mix 
(Sigma)
7.5μl
Forward Primer 
(M WG)
12.5μM 0.5μl
Reverse Primer 
(M WG)
12.5μM 0.5μl
cDNA 2μl
DEPC Water 4.5μl
15mlTotal
 
 
ARP (Acidic Ribosomal Protein; see Table 2.3 for primer details), a house keeping 
gene, was used to normalise for well to well variation and differences in extraction efficiency 
and cell number. Typical curves are shown in Figures 2.8 and 2.9. 
The data was collected on the Rotor-gene 7 program in order to set a threshold and 
gain the Ct values. These were then collated on to an Excel spread sheet and calculations 
made using comparative Ct method, also called 2-ΔΔCt method. This involved normalising the 
Ct values of the genes of interest (for example, MT1-MMP) to an endogenous housekeeping 
gene, ARP, resulting in the value ΔCt. Thereafter, the ΔCt values of the samples of interest 
(that is, varicose veins) were compared with the ΔCt values of reference or calibrator: 
ΔΔCt = ΔC t sample – ΔCt reference 
The mRNA levels were expressed as 2-ΔΔCt, and were first calculated for all samples 
(proximal and distal) relative to ΔCt of veins from other sources as reference.  
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Figure 2.8 The quantitation curves obtained for each gene and sample of interest, including 
the threshold at which the Ct values were calculated: MMP, TIMP and cytokines 
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Figure 2.9 The quantitation curves obtained for each gene and sample of interest, including 
the threshold at which the Ct values were calculated: HIF and ARP 
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at room temperature (20-22°C) for 30 minutes. Cells were placed in culture on fibronectin-
coated flasks and grown in M199 medium supplemented with heparin, endothelial cell growth 
supplement, antibiotic solution (200 units/ml penicillin and 200μg/ml streptomycin) and 10% 
heat inactivated human serum (from either non-diabetic patients with peripheral vascular 
disease greater than 65 years of age or from healthy donors less than 30 years of age) and 
maintained in humidified atmosphere of 5% CO2 in air at 37°C (Gosling et al. 1998). 
In order to immortalise the HSVEC they were taken at passage 2, cultured in 75cm2 
flasks until they reached 50% confluence. They were infected with two retroviral vectors, 
pZipSVtsA58-U19 which expresses the SV40 large T-antigen and pLXSN16E6E7 containing 
the E6 and E7 genes from HP16 in the presence of 8mg/ml polybrene. After 24 hours the 
virus-containing medium was discarded and fresh medium added. Cells were grown to 
confluence and then selected by supplementing the medium with 1mg/ml of the selective 
antibiotic G-418. The medium was changed twice weekly until the cells became confluent. 
The cells were detached using trypsin-EDTA solution and subcultured in 1:3 ratio in 25cm2 
flasks. Cell aliquots from each passage were frozen in medium containing 10% (v/v) DMSO 
and stored in liquid nitrogen (Scoumanne et al. 2002). 
The cells were removed from the liquid nitrogen, and defrosted in a water bath of 
37°C. They were placed in 5mls of the culture medium EGM 2 (Lonza Group Ltd, 
Switzerland) supplemented with 100U/ml penicillin, 100μg/ml streptomycin (BioWhittaker, 
Wokingham, UK) and 5% (v/v) heat inactivated foetal calf serum (FCS; Sigma UK) and then 
seeded onto 25cm2 gelatin coated flasks. The flasks were then checked daily under the 
microscope for cell confluence. The culture medium was changed twice weekly to provide 
continuing nourishment. Once confluent they were split. This involved the addition of 3mls 
0.25% trypsin/EDTA (Invitrogen Life Technologies, Paisley, UK) in order to cover the whole 
flask. 2mls of the trypsin/EDTA is then almost immediately removed before the cells detach. 
The flask was then left to incubate for a short while with the remaining 1ml of tryspin/EDTA 
while regularly checking for cell detachment under the microscope. Once the cells were 
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released from the base of the flask the mixture of the cells and the trypsin/EDTA were then 
split into 3 and placed in to new 25cm2 gelatin coated flasks and grown using the above 
culturing method until three identical confluent flasks were obtained (Figure 2.10) which 
were then exposed to differing degrees of hypoxia as explained in Section 2.3.3. 
 
Figure 2.10  Confluent HSVEC cells 
 
 
 
 
2.3.2 CULTURING HMEC-1 
HSVEC, obtained as described above, are venous endothelial cells and therefore a 
good model for the response of large vein endothelial cells to hypoxia (as might expected if 
venous stasis were the predominant cause of hypoxia in varicose vein disease). However, it is 
also possible that hypoxia might occur at the level of the vasa vasorum, due to venous wall 
hypertrophy and/or venous hypertension, small vessels (i.e. vasa vasorum) might also be 
exposed to hypoxia in patients varicose veins. Therefore, I also used micro vascular 
endothelial cells and studied their responses to hypoxia. 
HMEC-1 were obtained from Centers For Disease Control and Prevention 
(CDC)/National Centre for Infectious Diseases, Atlanta, Georgia USA. HMEC-1 (SV40 T 
antigen transformed dermal endothelial cells derived from human foreskin, pulmonary and 
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hepatic endothelium, which retain microvascular endothelial cell characteristics; Figure 2.11) 
have been cultured in 25cm2 non-coated flasks as these cells are adherent. They were fed 2-3 
times a week with 4mls RPMI-1640 medium supplemented with 100U/ml penicillin, 
100μg/ml streptomycin (BioWhittaker, Wokingham, UK) and 5% (v/v) heat inactivated foetal 
calf serum (FCS; Sigma UK). HMEC-1 cells were split after reaching confluence using the 
same method as previously described for HSVEC in Section 2.3.1. However, the HMEC-1 
cells were very sticky and took a little more time and vigor to detach them. The mixture of the 
cells and the trypsin/EDTA were then split into 3 and placed in to new 25cm2 flasks and 
grown using the above culturing method until three identical confluent flasks were obtained 
(Figure 2.11) which were then exposed to differing degrees of hypoxia as explained in 
Section 2.3.3. 
 
Figure 2.11 Confluent HMEC-1 
 
 
 
2.3.3 HYPOXIC EXPOSURE 
The cells were exposed to differing degrees of oxygen concentration in the RS 
Biotech Galaxy R incubator over a 24 hour period. Each cell line i.e. HSVEC and HMEC-1 
had 3 identical flasks of confluent cells. One of the identical flasks of cells underwent 
incubation for 24 hours in a 21% oxygen chamber - equivalent to normoxia. In parallel, 
another flask underwent 6 hours exposure to 1% oxygen and then moved back to normoxia to 
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complete the 24 hours, in order to create an acute hypoxia model. To represent chronic 
hypoxia, a flask from each cell line was exposed to 24 hours of 1% oxygen. Triplicates were 
completed for each experiment. 
On completion of the hypoxia experiment 350μls of a mixed solution of Buffer RLT 
and betamecaptaethanol (1ml Buffer RLT (QIAGEN GmbH, Germany ) with 10μl 
betamecaptaethanol (Merck & Co, N.J., USA )) was placed in each flask in order to lyse the 
cells and they were placed in the –80°C freezer until ready to proceed to RNA extraction. 
2.3.4 RNA EXTRACTION USING THE QIAAMP RNA BLOOD MINI KIT  
RNA was extracted from the cells using the QIAamp RNA blood mini kit 
(QIAGEN). The QIAamp RNA blood mini kit (QIAGEN GmbH, Germany) is a purposely 
designed kit with specialised shredder and spin columns together with collection tubes and 
reagents to ease RNA extraction from blood, tissues and cells. The suspension of cells was 
centrifuged at 1200 rpm for 10 minutes and a cell pellet was obtained after discarding the 
supernatant. 350μl of a cell lysis solution composed of 10μl of beta-mercaptoethanol per 1ml 
of Buffer RLT (QIAGEN) was added to the pellet of cells and dispersed by gently pipetting. 
The lysate was homogenised in a QIA shredder column by centrifuging for 2 minutes at 
maximal speed and collected in a 2 ml collection tube. After re-suspending the homogenised 
lysate in 350μl of 70% ethanol the sample was transferred into a QIAamp spin column 
containing a selective binding RNA silica-gel based membrane and spun for 15 seconds at 
8000 x g. The spin column was transferred into a new 2ml collection tube and 700μl of buffer 
RW1 (QIAGEN) was pipetted into the spin column and centrifuged for 15 seconds at 8000 x 
g. Contaminants were washed away with 500μl of buffer RPE by centrifuging the spin 
column for 15 seconds at 8000 x g, followed by a further 500μl washing at maximal 
centrifuging speed for 3 minutes. The final RNA product was obtained by washing the spin 
column with 50μl of RNase free water and centrifuging at 8000 x g for 1 minute and 
collecting the solute in a 1.5ml collection tube. Using the turbo DNase (Ambion, Austin, 
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USA) the 50μl of RNA was incubated with 1μl of DNase and 5μl of buffer at 37°C for 30 
minutes. The DNase enzyme was then inactivated with 5μl of DNase inactivation reagent by 
gently swirling for 2 minutes to optimise binding of the enzyme to the neutralising beads. The 
sample was then centrifuged at 10000g for 1 minute and the 55μl effluent pipetted out. 
Once mRNA was extracted and it was confirmed that there was no DNA present, the 
samples underwent reverse transcription in order to make cDNA which was then quantified 
by quantitative PCR. The results of were then analysed as previously described. All these 
methods have been previously described in full above. 
2.4 STATISTICAL ANALYSIS 
Data was compared and statistically analysed using the Graph Pad Prism software 
package (Graph Pad Software, CA, USA). Wilcoxon rank test was used to compare non-
parametrically distributed paired data, and paired Student’s t-test for normally distributed 
paired data. Mann-Whitney test was used to compare non-parametrically distributed unpaired 
data, and unpaired Student’s t-test for normally distributed unpaired data.  
Correlations were assessed using Spearman’s co-efficient for non-parametrically 
distributed data. Correlation displays a broad class of statistical relationships between two or 
more random variables or observed data values. Correlations are useful because they can 
indicate a predictive relationship that can be exploited in practice. Correlations can also 
suggest possible causal, or mechanistic relationships; however statistical dependence is not 
sufficient to demonstrate the presence of such a relationship. Rank correlation coefficients, 
such as Spearman's rank correlation coefficient as used in this thesis, measure the extent to 
which, as one variable increases, the other variable tends to increase, without requiring that 
increase to be represented by a linear relationship. If, as the one variable increase, the other 
decreases, the rank correlation coefficients will be negative. Power calculations were not 
performed, as I was not able to predict at the start where differences would occur. However, 
future studies can use my data as a basis for further assessing potential differences. 
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3 ASSESSMENT OF THE RELATIONSHIP BETWEEN MMP 
AND CYTOKINES IN VARICOSE VEINS 
 
3.1 INTRODUCTION 
There is a large amount of evidence to support the current theory that the balance 
between MMP and their inhibitors, TIMP, in a particular environment may determine the 
degrading potential of MMP (Borden and Heller 1997; Gomez et al. 1997; Nagase 1997). 
Within varicose veins this refers to the remodelling of the ECM. Previous studies have 
confirmed the presence of MMP-1, MMP-2, MMP-3, MMP-9, MMP-12, MMP-13 and 
TIMP-1 and TIMP-2 in both normal and varicose vein tissue (Gillespie et al. 2002; Woodside 
et al. 2003), although results have not always been consistent. A number of studies have 
examined at the relationship between TIMP-1 and MMP-2. It is has been widely shown that 
TIMP-1 activity tends to increase whilst MMP-2 activity decreases, resulting in an increased 
TIMP-1/MMP-2 ratio (Parra et al. 1998; Badier-Commander et al. 2000). This may partially 
explain why there is ECM accumulation in varicose veins. The mechanisms involved to 
regulate the MMP/TIMP balance are unknown, but potential candidates include cytokines 
and/or alterations in oxygen tension. 
Rafetto et al has shown that prolonged increases in vein wall tension had lead to 
increased expression of MMP-2 and MMP-9 and reduced contraction in the rat vena cava. 
This increased expression of MMP results in decreased contractility within the vessel and 
therefore promotes dilation. This study supports the theory that venous hypertension/stasis 
may play a very important role in the formation of varicose veins by mechanisms influencing 
MMP expression (Raffetto et al. 2008).  
Cytokines are small proteins that are secreted in response to an immune stimulus, that 
act quickly and locally, by mediating and regulating immunity, inflammation and 
haematopoiesis. They have been shown to increase or decrease the expression of membrane 
proteins, and to affect proliferation and secretion of effector molecules. Badier-Commander et 
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al compared levels of TGF-β, FGF-2 and VEGF in control and varicose veins. This study 
found that both TGFβ and FGF-2 were present in control veins and also varicose veins, 
although these cytokines were more abundant in the latter. No inflammatory cells were 
present which would indicate that there was no inflammatory mechanism responsible for the 
cytokine changes observed (Badier-Commander et al. 2001). Murphy et al also confirmed the 
presence of the cytokines, TNF-α and VEGF, in CVD and varicose vein disease. In fact the 
cytokine levels were raised when compared to a control group and then reversed with 
compression treatment. (Murphy et al. 2002). A similar study, looking at VEGF levels, by 
Hollingsworth et al attempted to induce blood stasis by application of a tourniquet for 10 
minutes. After induction of blood stasis the control group showed a clear increase in the mean 
levels of VEGF. In contrast, the varicose vein group showed no significant alteration in 
VEGF (Hollingsworth et al. 2001). Signorelli et al investigated levels of TNF-α, IL-1β and 
IL-6. The baseline of these were increased in varicose vein patients and became even more 
augmented when induced stasis was applied (Signorelli et al. 2000).  
MMP and TIMP have been shown to be stimulated by inflammatory cytokines, such 
as TNF-α and IL-1β (Borden and Heller 1997). 
 
3.2 OBJECTIVES 
There is a suggestion that MMP may be linked with inflammatory cytokine activity. 
The purpose of this component of my research was to investigate and determine the 
relationship between inflammatory and angiogenic cytokines with that of selected 
MMP/TIMP within varicose vein specimens, and addressed the question of whether vein wall 
remodelling is caused by cytokine-driven alterations in the MMP/TIMP balance. 
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3.3 MATERIALS AND METHODS 
3.3.1 PATIENT SELECTION AND TISSUE SAMPLING 
Varicose vein samples were obtained from patients from Charing Cross Hospital who 
required surgery for definitive management of their condition. Veins from other sources were 
used for comparison and these were obtained from patients undergoing arterial bypass, carotid 
endartarectomy operations, or arterio-venous fistula formation. Samples gained were 
immediately transferred to the laboratory and frozen using liquid nitrogen and then stored in 
the freezer (-80oC) until required. 
3.3.2 RNA EXTRACTION AND QUANTITATION 
Varicose vein tissue, including proximal and distal samples for each vein, and the 
veins from other sources was pulverised in a frozen state in order to preserve the RNA. The 
tissue was weighed and homogenised using TRIZOL Reagent (Invitogen Life Technologies, 
Paisley, UK). This maintains the integrity of the RNA while disrupting cells and dissolving 
cell components. RNA was then extracted using the method previously described in Section 
2.2. GAPDH PCR was performed in order to confirm the absence of genomic DNA. RNA 
was then quantified using a spectrophotometer and 500ng of RNA underwent reverse 
transcription reaction to prepare cDNA. Subsequently, RT-PCR was performed for each of 
the genes of interest in order to ensure amplification of a single discrete gene of interest band 
with no primer-dimer formation. Quantitative PCR using a Sybr Green Jumpstart Taq 
Readymix allowed sequential quantitative PCR runs, including non-template controls, to 
analyse the genes of interest and allow calculation of a Ct value from the quantitation curves. 
The genes of interest included the matrixmetalloproteinases MMP-2, MT1-MMP, TIMP-2 
and TIMP-3 and the cytokines VEGF, TNF-α, IL-1β and IL-6. 
3.3.3 STATISTICAL ANALYSES 
The data, in the form of a quantitation curve, were collected on the Rotor-gene 7 
program in order to set a threshold and obtain the Ct values. These were then collated on to an 
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Excel spread sheet and calculations made using comparative Ct method, also called 2-ΔΔCt 
method (see Chapter 2). The mRNA levels were then compared and statistically analysed 
using the Graph Pad Prism software package (Graph Pad Software, CA, USA). Wilcoxon 
rank test was used to compare non-parametrically distributed paired data, and paired-test for 
normally distributed paired data. Mann-Whitney test was used to compare non-parametrically 
distributed unpaired data, and unpaired-test for normally distributed unpaired data. 
Correlations were assessed using Spearman’s co-efficient. 
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3.4 RESULTS  
The following analyses were performed  
i) total varicose vein mRNA, expressed as fold change relative to a human cDNA 
sample, and compared to veins from other sources 
ii) comparison of total proximal versus total distal population of varicose veins 
(using data from fold change relative to a human cDNA sample) 
iii) comparison of paired proximal and distal varicose vein samples (using data from 
fold change relative to a human cDNA sample) 
3.4.1  MMP-2 EXPRESSION IN VARICOSE VEINS 
MMP-2 mRNA levels were quantified by PCR in the varicose vein samples and veins 
from other sources. MMP-2 mRNA levels in the varicose veins (median=2.29) were found to 
be similar to but if anything slightly elevated relative to veins from other sources 
(median=1.76; Figure 3.1). This was more apparent when comparing the range of data 
between the 2 populations; varicose veins (0.64 – 135.80) and veins from other sources (0.17 
– 31.56). This difference was not statistically significant (p=0.4629) using Mann-Whitney 
test. When data from the comparison of proximal and distal samples were examined, it 
appeared that MMP-2 mRNA was higher in distal varicose vein segments relative to the 
proximal varicose vein segments. However when the medians were compared, there was little 
difference, with the proximal (median=2.14) being similar to the distal (median=2.45; Figure 
3.2). Similar data was found when the samples were analysed as pairs (Figure 3.3). This 
difference was not statistically significant using Mann–Whitney test (p=0.5755) or by 
Wilcoxon signed rank test (p=0.4543) respectively.  
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Figure 3.1 MMP-2 mRNA levels in varicose vein segments and VOS 
MMP-2 mRNA levels in 30 varicose vein segments and 8 VOS segments, expressed relative to a 
human cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 MMP-2 mRNA levels in total proximal and distal varicose vein segments 
MMP-2 mRNA levels in 15 proximal and 15 distal varicose vein segments, expressed relative to a 
human cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 MMP-2 mRNA levels in paired proximal and distal vein segments 
MMP-2 mRNA levels in 15 paired varicose vein segments (distal and proximal), expressed relative to a 
human cDNA sample. 
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3.4.2 MT1-MMP EXPRESSION IN VARICOSE VEINS 
Furthermore, MT1-MMP mRNA levels were quantified by PCR in the varicose vein 
samples and  veins from other sources. When comparing median data, MT1-MMP mRNA 
levels in the varicose veins were found to be decreased (median=0.99) relative to the veins 
from other sources (median=7.56; Figure 3.4). However, this could be due to a larger 
population range in varicose veins (0.11 – 43.71 ) than that of veins from other sources (0.24 
– 20.18). This difference between veins from other sources and varicose veins was non-
significant (p=0.5040) using Mann-Whitney test. When data from the comparison of proximal 
and distal samples were examined, MT1-MMP mRNA was found to be higher in distal 
varicose vein segments (median=2.21) relative to the proximal varicose vein segments 
(median=0.97;Figure 3.5). A similar ratio was found when analysing paired proximal and 
distal segments (Figure 3.6). This difference was not statistically significant using Mann 
Whitney test (p=0.5614) and Wilcoxon signed rank test (p=0.2769).  
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Figure 3.4 MT1-MMP mRNA levels in varicose vein segments and VOS 
MT1-MMP mRNA levels in 30 varicose vein segments and 4 VOS segments, expressed relative to a 
human cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 MT1-MMP mRNA levels in total proximal and distal varicose vein 
segments 
MT1-MMP mRNA levels in 15 proximal and 15 distal varicose vein segments, expressed relative to a 
human cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 MT1-MMP mRNA levels in paired proximal and distal vein segments 
MT1-MMP mRNA levels in 15 paired varicose vein segments (distal and proximal), expressed relative 
to a human cDNA sample. 
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3.4.3 TIMP-2 EXPRESSION IN VARICOSE VEINS 
TIMP-2 mRNA levels were quantified by PCR in the varicose vein samples and veins 
from other sources. TIMP-2 mRNA levels in the varicose veins were found to be grossly 
elevated (median=1148.00) relative to the veins from other sources (median=1.61; Figure 
3.7). This data was statistically significant different using Mann Whitney test (p=0.0016). 
When data from the comparison of proximal and distal samples were examined, either alone 
or as paired samples, the range appeared to be equivalent, nevertheless TIMP-2 mRNA was 
found to be higher in distal varicose vein segments (median=1808.00) relative to the proximal 
varicose vein segments (median=754.80; Figure 3.8, Figure 3.9). This difference was not 
statistically significant using Mann-Whitney test (p=0.8357) or the Wilcoxon signed rank test 
(p=0.8904) respectively. 
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Figure 3.7 TIMP-2 mRNA levels in varicose vein segments and VOS 
TIMP-2 mRNA levels in 30 varicose vein segments and 7 VOS segments, expressed relative to a 
human cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 TIMP-2 mRNA levels in total proximal and distal varicose vein segments 
TIMP-2 mRNA levels in 15 proximal and 15 distal varicose vein segments, expressed relative to a 
human cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 TIMP-2 mRNA levels in paired proximal and distal vein segments 
TIMP-2 mRNA levels in 15 paired varicose vein segments (distal and proximal), expressed relative to 
a human cDNA sample. 
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3.4.4 TIMP-3 EXPRESSION IN VARICOSE VEINS 
TIMP-3 mRNA levels were quantified by PCR in the varicose vein samples and veins 
from other sources. TIMP-3 mRNA levels in the varicose veins (median=11.00) were also 
found to be grossly elevated relative to the veins from other sources (median=0.99; Figure 
3.10). This was highly significant using Mann Whitney test (p=0.0002). When data from the 
comparison of proximal and distal samples were examined, TIMP-3 mRNA was found to 
have broader range in distal varicose vein segments (2.02 – 58.89) relative to that of the 
proximal varicose vein segments (1.00 – 17.75). However comparison of their medians 
showed little difference with proximal (median=10.65) being equivalent to distal 
(median=12.73; Figure 3.11). Data were also available from 13 varicose vein matched pairs 
and again this showed little difference between distal varicose vein segments (median=12.73) 
relative to that of the proximal varicose vein segments (median=10.59; Figure 3.12). This 
difference was not statistically significant using Mann Whitney test (p=0.3693) and the 
Wilcoxon signed rank test (p=0.2734) respectively.  
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Figure 3.10 TIMP-3 mRNA levels in varicose vein segments and VOS 
TIMP-3 mRNA levels in 27 varicose vein segments and 7 VOS segments, expressed relative to a 
human cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 TIMP-3 mRNA levels in total proximal and distal varicose vein segments 
TIMP-3 mRNA levels in 14 proximal and 13 distal varicose vein segments, expressed relative to a 
human cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 TIMP-3 mRNA levels in paired proximal and distal vein segments 
TIMP-3 mRNA levels in 13 paired varicose vein segments (distal and proximal), expressed relative to 
a human cDNA sample. 
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3.4.5  VEGF EXPRESSION IN VARICOSE VEINS 
VEGF mRNA levels were quantified by PCR in the varicose vein samples and the 
veins from other sources. VEGF mRNA levels in the varicose veins were found to be slightly 
more abundant (median=0.81) than in veins from other sources (median=0.34; Figure 3.13). 
The range of data was similar in varicose vein segments (0.09 – 2.46) compared to veins from 
other sources (0.03 – 1.88). This data was not significant (p=0.2685) using the unpaired t-test. 
When examining the data from the comparison of proximal and distal samples, VEGF mRNA 
was found to be equivalent in distal varicose vein segments (median=0.73) relative to the 
proximal varicose vein segments (median=0.83; Figure 3.14). The range was also very similar 
in distal varicose vein segments (0.07 – 3.82) in comparison to that observed in proximal 
segments (0.09 – 2.24). Data were also available from the varicose vein matched pairs and 
again this showed that there was little difference in VEGF mRNA levels in distal varicose 
vein segments (median=0.73) relative to that of the proximal varicose vein segments 
(median=0.835; Figure 3.15). However both these comparisons were non-significant using 
unpaired t-test (p=0.9483) and paired t-test (p=0.8216) respectively.  
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Figure 3.13 VEGF mRNA levels in varicose vein segments and VOS 
VEGF mRNA levels in 29 varicose vein segments and 6 VOS segments, expressed relative to a human 
cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 VEGF mRNA levels in total proximal and distal varicose vein segments 
VEGF mRNA levels in 15 proximal and 14 distal varicose vein segments, expressed relative to a 
human cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 VEGF mRNA levels in paired proximal and distal vein segments 
VEGF mRNA levels in 14 paired varicose vein segments (distal and proximal), expressed relative to a 
human cDNA sample. 
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3.4.6 TNF-α EXPRESSION IN VARICOSE VEINS 
TNF-α mRNA levels were quantified by PCR in the varicose vein samples and the 
veins from other sources. TNF-α mRNA levels in the varicose veins (0.32 – 104.70) were 
found to be elevated relative to the veins from other sources (0.13 – 33.71; Figure 3.16). This 
is also reflected when comparing the medians, with there being more TNF-α mRNA in 
varicose vein samples (median=11.79) than in veins from other sources (median=1.97). These 
data were not significant (p=0.1317) using Mann-Whitney test. When data from the 
comparison of proximal and distal samples were studied, the trend seemed to suggest that 
TNF-α mRNA may be slightly increased in distal varicose vein segments relative to that of 
the proximal varicose vein segments (Figure 3.17). However when the medians were analysed 
it showed that there was a lower mRNA level in distal veins (median=10.28) than proximal 
(median=13.09). Data was also available from the varicose vein matched pairs and again this 
showed that TNF-α was lower in distal varicose vein segments (median=10.28) relative to 
proximal varicose vein segments (median=13.16; Figure 3.18). However both these 
comparisons were non-significant using Mann Whitney test (p=0.9826) and Wilcoxon signed 
rank test (p=1.00) respectively. Overall this equates to similar TNF-α mRNA expression in 
distal varicose veins and proximal varicose veins. 
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Figure 3.16 TNF-α mRNA levels in varicose vein segments and VOS 
TNF-α mRNA levels in 31 varicose vein segments and 6 VOS segments, expressed relative to a human 
cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 TNF-α mRNA levels in total proximal and distal varicose vein segments 
TNF-α mRNA levels in 15 proximal and 14 distal varicose vein segments, expressed relative to a 
human cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18 TNF-α mRNA levels in paired proximal and distal vein segments 
TNF-α mRNA levels in 14 paired varicose vein segments (distal and proximal), expressed relative to a 
human cDNA sample.  
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3.4.7 IL-1β EXPRESSION IN VARICOSE VEINS 
IL-1β mRNA levels were quantified by PCR in the varicose vein samples and were 
found to be significantly underexpressed relative to veins from other sources (p=0.0111, 
Figure 3.19) using Mann-Whitney test. This is not obviously reflected by the graph as the data 
revealed a wider range of mRNA expression of IL-1β in varicose vein segments (0.01 – 8.49) 
compared to veins from other sources (0.93 – 5.31). However, the varicose vein samples have 
a lower median (median=0.22) in comparison to veins from other sources (median=1.68). 
When examining the data from the comparison of proximal and distal samples, it appears that 
proximal and distal levels are equivalent despite the increased range of levels found in distal 
varicose vein segments. This is confirmed by comparing the median and inter-quartile ranges. 
Distal varicose vein segments (median=0.36) are similar to proximal varicose vein segments 
(median=0.19; Figure 3.20). Data was also available from the varicose vein matched pairs and 
again this showed little difference between distal varicose vein segments (median=0.25) 
relative to that of the proximal varicose vein segments (median=0.19; Figure 3.21). Both 
these comparisons were non-significant using the Mann Whitney test (p=0.5222) and 
Wilcoxon signed rank test (p=0.2969) respectively.  
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Figure 3.19 IL-1β mRNA levels in varicose vein segments and VOS 
IL-1β mRNA levels in 21 varicose vein segments and 5 VOS segments, expressed relative to a human 
cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20 IL-1β mRNA levels in total proximal and distal varicose vein segments 
IL-1β mRNA levels in 12 proximal and 9 distal varicose vein segments, expressed relative to a human 
cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21 IL-1β mRNA levels in paired proximal and distal vein segments 
IL-1β mRNA levels in 7 paired varicose vein segments (distal and proximal expressed relative to a 
human cDNA sample. 
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3.4.8 IL-6 EXPRESSION IN VARICOSE VEINS  
IL-6 mRNA levels were quantified by PCR in varicose vein samples and veins from 
other sources. Varicose vein samples (median=3.12) appeared to be decreased relative to the 
veins from other sources (median=5.98; Figure 3.22). This trend also occurred with the ranges 
of the two sets of results. The range was a lot smaller in the varicose vein segments (0.04 – 
30.06) when compared to the veins from other sources (1.00-320.70). Despite this the data 
was non-significant (p=0.5510) using the Mann-Whitney test. When looking at the data from 
the comparison of proximal and distal samples, IL-6 mRNA appeared to be slightly lower in 
distal varicose vein segments relative to proximal segments. However, when the medians 
were compared distal varicose vein segments (median=3.07) were equivalent to proximal 
varicose vein segments (median=3.19; Figure 3.23). Data was also available from the varicose 
vein matched pairs and again this showed that IL-6 levels were similar in distal varicose vein 
segments (median=3.67) relative to the proximal varicose vein segments (median=3.07; 
Figure 3.24). Both these comparisons were non-significant using the Mann Whitney test 
(p=0.5441) and Wilcoxon signed rank test (p=0.7334).  
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Figure 3.22 IL-6 mRNA levels in varicose vein segments and VOS 
IL-6 mRNA levels in 27 varicose vein segments and 7 VOS segments, expressed relative to a human 
cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23 IL-6 mRNA levels in total proximal and distal varicose vein segments 
IL-6 mRNA levels in 13 proximal and 14 distal varicose vein segments, expressed relative to a human 
cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24 IL-6 mRNA levels in paired proximal and distal vein segments 
IL-6 mRNA levels in 12 paired varicose vein segments (distal and proximal), expressed relative to a 
human cDNA sample. 
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3.4.9 CORRELATION OF CYTOKINES TO MATRIX METALLOPROTEINASES AND THEIR 
TISSUE INHIBITORS 
To analyse the relationship between cytokines and MMPs and their inhibitors, mRNA 
levels for cytokines were compared to mRNA of MMP and TIMP in the same samples. 
Significance was analysed using the Spearman correlation co-efficient (r), and p values of less 
than 0.05 were considered statistically significant. 
VEGF expression was compared with the expression of MMP-2 (r=0.0116), MT1-
MMP (r=-0.0692), TIMP-2 (r=-0.0214) and TIMP-3 (r=0.4647; Figure 3.25). The former 3 
values showed no significant correlation; however there was a significant correlation between 
VEGF expression and TIMP-3 expression (p=0.0146). 
Similarly, TNF-α expression was compared with the expression of MMP-2 
(r=0.6499), MT1-MMP (r=0.3777), TIMP-2 (r=0.5658) and TIMP-3 (r=0.0425;Figure 3.26). 
TNF-α showed highly significant correlation with MMP-2 (p<0.0001) and TIMP-2 
(p=0.0014), and significant correlation with TIMP-3 (p=0.0272) and MT1-MMP (p=0.0434). 
IL-1β expression was compared with expression for MMP-2 (r=0.5406), MT1-MMP 
(r=0.4392), TIMP-2 (r=0.5854) and TIMP-3 (r=-0.0369; Figure 3.27). IL-1 β showed 
significant correlation with MMP-2 (p=0.0114), MT1-MMP (p=0.0464) and TIMP-2 
(p=0.0053). In contrast, there was no significant correlation between IL-1 β and TIMP-3. 
Finally, IL-6 expression was compared with the expression of MMP-2 (r=0.1566), 
MT1-MMP (r=0.1169), TIMP-2 (r=0.2277) and TIMP-3 (r=0.2123; Figure 3.28). There was 
no significant correlation between IL-6 and any of these parameters. 
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Figure 3.25 Correlation of VEGF and MMP/TIMP expression in varicose veins  
VEGF expression versus (a) MMP-2 expression; (b) MT1-MMP expression; (c) TIMP-2 expression; 
(d) TIMP-3 expression. 
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Figure 3.26 Correlation of TNF-α and MMP/TIMP expression in varicose veins  
TNF-α expression versus (a) MMP-2 expression; (b) MT1-MMP expression; (c) TIMP-2 expression; 
(d) TIMP-3 expression. 
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Figure 3.27 Correlation of IL-1β and MMP/TIMP expression in varicose veins  
IL-1β expression versus (a) MMP-2 expression; (b) MT1-MMP expression; (c) TIMP-2 expression; (d) 
TIMP-3 expression. 
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Figure 3.28 Correlation of IL-6 and MMP/TIMP expression in varicose veins  
IL-6 expression versus (a) MMP-2 expression; (b) MT1-MMP expression; (c) TIMP-2 expression; (d) 
TIMP-3 expression. 
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3.5 DISCUSSION 
This chapter set out to assess the relationship between inflammatory cytokine 
expression and matrix degrading MMP and their inhibitors in varicose veins. This was 
addressed by quantifying and comparing mRNA expression for specific genes of interest in 
proximal and distal portions of varicose vein tissue and veins from other sources. The genes 
of interest chosen were MMP and their inhibitors MMP-2, MT1-MMP, TIMP-2 and TIMP-3, 
and the cytokines VEGF, TNF-α, IL-1β and IL-6.  
I have confirmed that the mRNA for MMP-2, MT1-MMP, TIMP-1 and TIMP-2 are all 
expressed in varicose vein tissue. When these were compared to veins from other sources 
there was no difference in the mRNA expression for the MMP, MMP-2 or MT1-MMP. 
Present literature is conflicting. Norgauer et al would suggest in biopsies taken from patients 
with venous leg ulcers there is increased expression of MMP-2 and MT1-MMP (Norgauer et 
al. 2002). Rafetto et al would also agree that MMP-2 expression increases and they suggest 
that this is because of the effect of venous hypertension on the vein wall (Raffetto et al. 
2008). In contrast, Takase et al induced venous hypertension in femoral veins of rats and used 
the contralateral vein as a control and was unable to generate any change in MMP-2 
expression (Takase et al. 2004). There was however, a significant increase in my study in the 
amount of mRNA expressed for TIMP-2 and TIMP-3 in varicose vein tissue when compared 
to veins from other sources. Again there is no consensus on the literature. Woodside et al 
demonstrated by Western blot analysis that only small quantities of TIMP-1 and TIMP-2 
protein isolates were present in varicose veins and veins from other sources, neither of which 
could be detected by immunohistochemistry (Woodside et al. 2003). In contrast Bader-
Commander et al found high TIMP-1 levels and low MMP-2 level/activity in varicose veins 
resulting in a three-fold increase in the TIMP-1/MMP-2 ratio in varicose versus control veins 
(Badier-Commander et al. 2000). Herouy et al also support Bader-Commander et al. They 
concluded from the work they have performed on venous leg ulcers that MMP-2 was 
imbalanced by the locally reduced expression of TIMP-2 (Herouy et al. 1998). Our results 
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would echo these thoughts. I found no change to MMP-2 and MT1-MMP expression when 
compared with veins from other sources and a significant increase in TIMP-2 and TIMP-3 
expression. This would suggest that the MMP/TIMP imbalance is disrupted by the over-
expression of TIMP. 
Regional variation in the literature has only commented on MMP-1 and MMP-13 
where both matrixins are more abundant in the proximal segment (Gillespie et al. 2002). 
When analysing our data comparing proximal varicose vein tissue and distal varicose vein 
tissue, MT1-MMP mRNA was found to be more abundantly expressed in distal VV segments 
relative to proximal varicose vein segments. This is consistent with the protein and 
preliminary data obtained by my predecessor (Aravind 2007). However, despite an increase in 
expression and an obvious trend, this data was not statistically significant. TIMP-2, and also 
TIMP-3, is obviously abundantly expressed in varicose vein tissue. On analysis of the TIMP-
2 graphs, either alone or paired, there was no obvious regional variation. However, 
comparison of the medians between these sample groups indicate that TIMP-2 mRNA levels 
were 2-fold higher in distal varicose vein segments relative to proximal segments. This result 
is non-significant. MMP-2 and TIMP-3 consistently showed no difference between the two 
anatomical sites. It is interesting that MT1-MMP and TIMP-2 both show a tendency to be 
more abundant in the distal portion of varicose vein and that there appears to be no regional 
variation in MMP-2. We know that the activation of MMP-2 is promoted by TIMP-2 binding 
to the membrane bound receptor MT1-MMP. The fact that there is no change in MMP-2 
levels would support some recent research by D’Alessio et al that the interaction of TIMP-2 
and MT1-MMP controls cell functions by a mechanism independent of ECM degradation 
(D'Alessio et al. 2008). It also of interest that distal segments of varicose veins tend to be 
thinner which suggests that MMP/TIMP balance may favour matrix degradation in these 
areas. 
I have also confirmed that mRNA for the cytokines VEGF, TNF-α, IL-1β and IL-6 are 
expressed in varicose vein tissue. When varicose vein samples were compared to veins from 
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other sources, there was increased mRNA expression for VEGF and TNF-α in varicose vein 
tissue, 2-fold and 5-fold respectively. This data was not significant but can be supported by 
Yasim et al, who took blood from the brachial vein in patients with primary varicose veins 
and compared the results with healthy volunteers. They compared the plasma levels of VEGF 
and found that they were statistically higher in the study group than in the control group 
(Yasim et al. 2008). Again, the literature is inconsistent. Signorelli et al also found elevated 
production of TNF-α in varicose vein disease that became further increased with an artificial 
increase in venous hypertension by tourniquet application. They also found that IL-1β and IL-
6 increased under the same conditions (Signorelli et al. 2000). In contrast, Pappas et al 
measured the systemic, soluble, serum cytokine levels between healthy controls and patients 
with CVI. IL-6 was elevated in patients with CVD, while TNF-α and IL-1β, demonstrated no 
significant difference between the groups (Pappas et al. 1995). My results showed that the 
interleukins IL-1β and IL-6 both had a reduction in mRNA expression in varicose vein tissue 
when compared to veins from other sources. For IL-1β this result was significant.  
When analysing data comparing proximal versus distal varicose vein samples, VEGF, 
IL-1β and IL-6 consistently showed no difference between the two anatomical areas. TNF-α, 
on the other hand, displayed more expression in the proximal portion of the varicose vein that 
in the distal portion when comparing the median values, but this data was not significant. 
There is no data supporting regional variations of cytokines in varicose veins. 
When correlating the cytokines with MMP and their inhibitors, VEGF displayed a 
statistically significant correlation with TIMP-3. It has been reported that TIMP-3 blocks the 
binding of VEGF to VEGF receptor type 2 and inhibits downstream signalling and 
angiogenesis (Qi et al. 2003). Thus an increase in TIMP-3, to counter-act the possible pro-
angiogenic effects of VEGF, may be a mechanism to regulate angiogenesis in varicose vein 
adventitia. In contrast, TNF-α showed a significant correlation with MT1-MMP and TIMP-3 
and a very significant correlation with MMP-2 and TIMP-2. IL-1β also significantly 
correlated with MMP-2, MT1-MMP and TIMP-2. These data are of potential interest, since 
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active MT1-MMP and TIMP-2 are thought to bind pro-MMP-2 forming a ternary complex, 
which permits pro-MMP-2 activation by TIMP-2-free MT1-MMP. TIMP-2 bound to MT1-
MMP on the cell surface is thought to act as a receptor for proMMP-2, with homophilic 
complex formation by MT1-MMP (Itoh et al. 2001). The fact that both TNF-α and IL-1β 
levels correlate with the expression of the 3 members of this complex may provide evidence 
that in varicose veins cytokine-mediated assembly of this complex could be important in 
regulating matrix turnover. TNF-α also correlated with TIMP-3. This is not all together 
surprising, TNF-α and TIMP-3 have a strong link via TNF-α converting enzyme (TACE). 
TACE is a membrane bound disintegrin metalloproteinase that processes the membrane 
bound cytokine pro TNF-α into an active, soluble form, TNF-α. TACE was found to be well 
inhibited TIMP-3 but not by TIMP-1, -2 and -4. These results suggest that TIMP-3 may be 
important in the modulation of pathological events in which TNF-α secretion is involved 
(Amour et al. 1998), such as apoptosis. IL-6 did not correlate with any of the MMP or their 
inhibitors. 
There were some limitations during my research period. Due to the surgical 
reformation of varicose vein treatment, less and less pathological tissue was available as my 
project progressed. The frequent “open high tie and strip” operation was rapidly replaced by 
the more minimally invasive endovenous surgery. This meant that tissue from the 
saphenofemoral junction was no longer available for my studies. Tissue was only available 
from phlebectomies or avulsions. This in itself has implications for interpretation of my data. 
In my introduction (Chapter 1) I explained that varicose veins were considered to be a multi-
segmental problem, with potential for regional variations along the vein length. When tissue 
was taken from the saphenofemoral junction (proximal segment) together with a portion of 
the GSV just below the knee (distal segment) during the traditional stripping method, this was 
by definition from patients that have some form of varicose vein disease. However, the 
“distal” and “proximal” segments utilised in this study were not necessarily diseased. It would 
be interesting to analyse in a comparable study avulsed segments which are by definition 
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veins that are prominent, dilated and tortuous. 
Furthermore, it would also have been ideal to have been able to have been more 
selective about patients that were included in the study with regards to co-morbidities. 
Unfortunately, the co-morbidities of patients who could provide veins from other sources 
were plentiful and I was unable to exclude them from the study, otherwise the population of 
patients for comparison would have been non-existent due to ethical constraints. The ideal 
“control” patient would be a young healthy patient, who potentially required an operation for 
trauma in order to extract a sample of vein. These patients were not readily available to me in 
this study. It would have also been preferable to age match the varicose vein group and the 
controls. However, the patients from whom veins from other sources were obtained were of 
necessity an older group, although both groups were matched by gender. Much of the data 
compared proximal versus matched distal segments, which are not affected by these factors. 
Nevertheless, to confidently compare varicose vein tissue and veins from other sources, a 
larger and better matched “control” group would have been preferable. 
From a technical perspective, RNA extraction from tissue itself was difficult and I 
needed to establish and validate this method in the laboratory. Many methods were attempted 
before RNA was successfully extracted using the method explained in Section 2.2. It appears 
that venous tissue is very tough and that breaking it down into smaller components was only 
possible when in frozen form. Of particular importance, it was challenging to obtain RNA 
from some of the control tissue. The facial veins retrieved during carotid surgery were very 
small and did not provide sufficient tissue alone to get a satisfactory yield of RNA. This was 
overcome by combining 4 individual specimens together. 
When performing the quantitative PCR the housekeeping gene (ARP) that I used was 
itself relatively low in abundance. ARP does not change under conditions of hypoxia, and is 
therefore appropriate for this study. The 2-ΔΔCt method was used to calculate relative amounts 
of mRNA, which compares the gene of interest to the housekeeping gene (ARP). Low 
abundance of the housekeeping gene could therefore result in artificially large changes in 
gene expression. Nevertheless, initial data from a subsequent study on varicose veins using 
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18S ribosomal RNA as the housekeeping gene confirms many of my findings. 
In summary, this chapter has shown that cytokines, growth factors and MMP/TIMP 
are expressed in varicose veins. Furthermore, the upregulation of TIMP-2 and TIMP-3 may 
cause an imbalance in the MMP/TIMP ratio, thereby contributing to varicose vein 
development. Since growth factors such as VEGF and MMP (particularly MT1-MMP and 
MMP-2) are potentially affected by hypoxia, the next part of my study (Chapter 4) aimed to 
assess HIF expression in varicose veins.  
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4 ASSESSMENT OF HIF EXPRESSION IN VARICOSE 
VEINS 
 
4.1 INTRODUCTION 
Hypoxia has been suggested as being involved in varicose vein disease, but there is 
little work concentrating on the possibility and perhaps subsequent effects of hypoxia in either 
the venous macrocirculation or microcirculation of the leg. As previously mentioned in detail 
in Chapter 1, hypoxia has been sub-divided by time span, acute and chronic hypoxia.  
Michiels et al has proven that HSVEC respond like other endothelial cells when 
exposed to hypoxia. They incubated human saphenous veins in normoxic and hypoxic 
conditions and observed the interactions between the endothelium and neutrophils using 
electron microscopy and histological observation to confirm the results. They concluded that 
when hypoxia occurs, endothelial cells get activated causing them to release inflammatory 
mediators which aid the neutrophils to adhere, and subsequently activate themselves. The 
activated leukocytes then release free radicals and proteases which directly degrade the ECM. 
Activation of endothelial cells also directly trigger smooth muscle cell proliferation and 
synthesis of the extracellular components causing an imbalance. If this process is frequently 
repeated it is likely to lead to alterations in the venous wall similar to that seen in varicose 
veins (Michiels et al. 1997). 
There is no clear evidence of how the initial insult of hypoxia occur in the venous 
system in order to promote varicose vein development but potential possibilities include: 1) 
blood stasis causing macrocirulatory ischemia damaging the endothelial cells of the intima, 2) 
hypoxia to the endothelial wall caused by insufficient supply by the vasa vasorum in the 
adventitia and 3) tissue hypoxia due to alterations in the microcirculation. It is controversial 
as to whether or not blood stasis is present in varicose vein disease and, if it does, how it 
causes its insult. Potentially, inflammatory mediators will recruit and activate neutrophils 
which infiltrate the venous wall and damage components of the ECM. It could also be that 
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growth factors induce smooth muscle cell migration, proliferation and de-differentiation in to 
the synthetic phenotype leading to the formation of the neointima. Both of these processes 
over time would eventually cause the alterations of the venous wall that have been observed 
in varicose veins (Michiels et al. 2002).  
It is thought, by some, that standing promotes blood stasis in the lower limbs and that 
such stasis will promote ischemia decreasing the oxygen availability to the tissues. This is 
logical as due to gravitational pull and the lack of the “calf muscle pump” action, as seen in 
varicose veins, there is a lack of venous return. Gaylarde et al has supported this hypothesis 
by showing there is a link between stasis and hypoxia, reporting improvement in skin blood 
flow by application of external compression stockings in standing subjects thus preventing 
microcirculatory stasis secondary to venous hypertension (Gaylarde et al. 1993). Alterations 
in the microcirculation in CVI are thought to be due to a mixture of venous stasis, high 
capillary pressure and anoxic tissue. Matic et al has reported that the partial pressure of 
oxygen is higher in ulcerated limbs than those without ulceration which they suggest is due to 
blood passing directly from arterioles to venules over arterio-venous temperature-regulating 
shunts in the dermis (Matic et al. 2000). However another study found significant skin 
hypoxia in patients with venous disease and skin ulcerations (Clyne et al. 1985).  
 
4.2 OBJECTIVES 
This part of the research focused on correlating the expression at the mRNA level of 
hypoxia-inducible transcription factors, HIF-1α and HIF-2α, in varicose vein specimens. As 
for the studies of MMP/TIMP and cytokine expression, this analysis was performed for 
varicose veins and veins from other sources, as well as for regional variation (proximal versus 
distal varicose vein segments in the same patient). 
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4.3 MATERIALS AND METHODS 
4.3.1 PATIENT SELECTION AND TISSUE SAMPLING 
Varicose vein samples were obtained from patients as well as veins from other 
sources that were used for comparison. This has been previously described in material and 
methods Section 2.1. Samples gained were immediately frozen using liquid nitrogen and then 
stored in the freezer (-80oC) until required. 
4.3.2 RNA EXTRACTION AND QUANTITATION 
Similarly to Chapter 3, Varicose vein tissue, including proximal and distal samples 
for each vein, and veins from other sources were pulverised in a frozen state in order to 
preserve the RNA. The tissue was weighed and underwent homogenization, RNA extraction 
and reverse transcription. Quantitative PCR was finally used analyse the genes of interest and 
allow calculation of a Ct value from the quantitation curves. The genes of interest included 
the MMPs HIF-1α and HIF-2α. Comparisons were made to the data collected in chapter 3 for 
the MMPs MMP-2, MT1-MMP, TIMP-2 and TIMP-3 and the cytokines VEGF, TNF-α, IL-
1β and IL-6. 
4.3.3 STATISTICAL ANALYSES 
The data was collected on the Rotor-gene 7 program, a threshold set and Ct values 
obtained. These were collated on to an Excel spread sheet and calculations made using 
comparative Ct method (see Chapter 2). The mRNA levels were then compared and 
statistically analysed using the Graph Pad Prism software package (Graph Pad Software, CA, 
USA). Wilcoxon rank test was used to compare non-parametrically distributed paired data, 
and paired-test for normally distributed paired data. Mann-Whitney test was used to compare 
non-parametrically distributed unpaired data, and unpaired-test for normally distributed 
unpaired data. Correlations were assessed using Spearman’s co-efficient for non-
parametrically distributed data. 
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4.4 RESULTS  
The following analyses were performed  
i) total varicose vein mRNA, expressed as fold change relative to a human cDNA 
sample, and compared to veins from other sources 
ii) comparison of total proximal versus total distal population of varicose veins 
(using data from fold change relative to a human cDNA sample) 
iii) comparison of paired proximal and distal varicose vein samples (using data from 
fold change relative to a human cDNA sample) 
4.4.1 HIF-1α EXPRESSION IN VARICOSE VEINS 
HIF-1α mRNA levels were quantified by PCR in the varicose vein samples and the 
veins from other sources. HIF-1α mRNA levels in the varicose veins (median = 0.42) were 
found to be much less to those in the veins from other sources (median = 32.46; Figure 4.1) 
This data was significant using the Mann Whitney test (p=0.0121). When data from the 
comparison of proximal and distal samples were examined, it appeared that HIF-1α mRNA 
was equivalent in distal varicose vein segments (median = 0.41) relative to the proximal 
varicose vein segments (median = 0.43; Figure 4.2) despite a slightly wider range of data in 
the distal varicose vein segments. This difference was not statistically significant using Mann 
Whitney test (p=0.8786). This was confirmed when the samples were analysed as paired 
samples (Wilcoxon signed rank test p=0.9515; Figure 4.3).  
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Figure 4.1 HIF-1α mRNA levels in varicose vein segments and VOS 
HIF-1α mRNA levels in 29 varicose vein segments and 4 VOS segments, expressed relative to a 
human cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum. 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 HIF-1α mRNA levels in total proximal and distal varicose vein segments 
HIF-1α mRNA levels in 14 proximal and 15 distal varicose vein segments, expressed relative to a 
human cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 HIF-1α mRNA levels in paired proximal and distal vein segments 
HIF-1α mRNA levels in 14 paired varicose vein segments (distal and proximal), expressed relative to a 
human cDNA sample. 
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4.4.2 HIF-2α EXPRESSION IN VARICOSE VEINS 
HIF-2α mRNA levels were quantified by PCR in the varicose vein samples and veins 
from other sources. Similarly to HIF-1α, HIF-2α mRNA levels in the veins from other 
sources were found to be significantly elevated (median = 370.90) relative to the varicose 
vein samples (median = 3.42) using the Mann Whitney test (p=0.0372; Figure 4.4). When 
data from the comparison of proximal and distal samples was reviewed it appeared, again 
similarly to HIF-1α, that there was little difference between the two areas. However, when 
comparing the medians there is an apparent difference, with HIF-2α being more abundant in 
proximal samples (median = 8.02) in comparison to distal samples (median = 2.27; Figure 
4.5). When comparing paired samples the medians are in a much closer range (proximal = 
3.66, distal = 2.41; Figure 4.6). Neither sets of data showed significance using Mann Whitney 
(p=0.3012) for the former and Wilcoxon signed rank test (p=0.8926) for the latter.  
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 Figure 4.4 HIF-2α mRNA levels in varicose vein segments and VOS 
HIF-2α mRNA levels in 28 varicose vein segments and 5 VOS segments, expressed relative to a 
human cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum. 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 HIF-2α mRNA levels in total proximal and distal varicose vein segments 
HIF-2α mRNA levels in 14 proximal and 14 distal varicose vein segments, expressed relative to a 
human cDNA sample. Data are medians plus inter-quartile (IQ) range, and maximum/minimum 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 HIF-2α mRNA levels in paired proximal and distal vein segments 
HIF-2α mRNA levels in 13 paired varicose vein segments (distal and proximal), expressed relative to a 
human cDNA sample. 
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4.4.3 CORRELATION OF HIF-1α AND HIF-2α TO MATRIX METALLOPROTEINASES, 
THEIR TISSUE INHIBITORS AND TO CYTOKINES 
To analyse the relationship between HIF-1α and HIF-2α with MMP, their inhibitors 
and cytokines, the mRNA levels of HIFs were compared to the mRNA of MMP, TIMP and 
the cytokines, VEGF, TNF-α, IL-1β and IL-6. Significance was analysed using the Spearman 
correlation co-efficient (r) , and p values of less than 0.05 were considered statistically 
significant.  
HIF-1α expression was compared with expression of MMP-2 (r=0.4456), MT1-MMP 
(r=0.3242), TIMP-2 (r=0.3920) and TIMP-3 (r=0.3563; Figure 4.7). HIF-1α showed 
significant correlation with MMP-2 (p=0.0154) and TIMP-2 (p=0.0355).  
HIF-1α expression was also compared with the expression of VEGF (r=0.3652), 
TNF-α (r=0.4412), IL-1β (r=0.5900) and IL-6 (r=-0.0113; Figure 4.8). HIF-1α showed 
significant correlation with TNF-α (p=0.0188) and IL-1β (p=0.0049).  
HIF-2α expression was compared with expression of MMP-2 (r=0.2543), MT1-MMP 
(r=0.5188), TIMP-2 (r=0.3027) and TIMP-3 (r=0.1556; Figure 4.9). HIF-2α showed 
significant correlation with MT1-MMP (p=0.0047). There was no significant correlation 
between HIF-2α and MMP-2, TIMP-2 or TIMP-3. 
HIF-2α expression was compared with the expression for VEGF (r=-0.0089), TNF-α 
(r=0.4151), IL-1β (r=0.2937) and IL-6 (r=0.2259; Figure 4.10). There was significant 
correlation between HIF-2α and TNF-α (p=0.0313). There was no significant correlation 
between HIF-2α and any of the other cytokines analysed. 
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Figure 4.7 Correlation of HIF-1α and MMP/TIMP expression in varicose veins  
HIF-1α expression versus (a) MMP-2 expression; (b) MT1-MMP expression; (c) TIMP-2 expression; 
(d) TIMP-3 expression. 
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Figure 4.8 Correlation of HIF-1α and cytokine expression in varicose veins  
HIF-1α expression versus (a) VEGF expression; (b) TNF-α expression; (c) IL-1β  expression; (d) IL-6 
expression. 
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Figure 4.9 Correlation of HIF-2α and MMP/TIMP expression in varicose veins  
HIF-2α expression versus (a) MMP-2 expression; (b) MT1-MMP expression; (c) TIMP-2 expression; 
(d) TIMP-3 expression. 
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Figure 4.10 Correlation of HIF-2α and cytokine expression in varicose veins  
HIF-2α expression versus (a) VEGF expression; (b) TNF-α expression; (c) IL-1β  expression; (d) IL-6 
expression. 
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4.5 DISCUSSION 
Research has shown that hypoxia may regulate MMPs and their inhibitors. HIFs are 
the transcription factors that mediate the adaptive response to hypoxia. As previously 
described in Section 1.5.4.2, in order to prevent the accumulation of HIF protein, VHL 
ubiquitin ligase binds to the prolyl hydroxylated HIF (the alpha subunit of either HIF-1 or 
HIF-2) complex, and promotes destruction via the proteasome pathway. In the context of 
varicose vein development, there is no clear evidence to suggest a possible mechanism of how 
the initial insult of hypoxia could be brought about. Blood stasis secondary to an increase in 
venous hypertension may cause microcirculatory ischemia damaging the endothelial cells of 
the intima, insufficient oxygen supply by the vasa vasorum in the adventitia direct to the 
endothelial wall could cause hypoxic insult or surrounding tissue hypoxia could occur due to 
alterations in the microcirculation.  
This chapter set out to investigate if hypoxia is a feature of varicose veins and whether 
there is any effect or association with MMP or cytokine expression. This was addressed by 
quantifying and comparing mRNA expression for HIF-1α and HIF-2α in proximal and distal 
portions of varicose vein tissue and veins from other sources. The results were then compared 
to the MMPs and their inhibitors, MMP-2, MT1-MMP, TIMP-2 and TIMP-3, and the 
cytokines VEGF, TNF-α, IL-1β and IL-6 (described in Chapter 3). There have been few 
studies that have examined the contribution of changes in oxygen tension to varicose vein 
disease. This is somewhat surprising, since varicose veins by nature involve alterations in 
blood flow and venous stasis which must compromise tissue oxygenation, and hence involve 
alteration in HIF expression. However, there is presently no data relating to HIF expression in 
varicose vein disease. 
I have confirmed, for the very first time that, that mRNA for HIF-1α and HIF-2α are 
expressed in varicose vein tissue. When these were compared to veins from other sources the 
mRNA expression in varicose vein tissue was significantly decreased for both HIF-1α and 
HIF-2α. This is an unexpected result. If hypoxia is a feature of varicose vein disease one 
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would have expected levels of HIF, a transcription factor that are activated in response to 
periods of hypoxia-induced physiological stress, to have increased in comparison to veins 
from other sources. This obscure result can only be explained by the fact that all the 
expression levels for HIF-1α and HIF-2α were very low. The only way to confirm this result 
is to measure the HIF-1α and HIF-2α protein levels in varicose veins and veins from other 
sources. 
When analysing data comparing proximal versus distal varicose vein samples, HIF-
1α consistently showed no difference between the two anatomical areas. On the other hand, 
despite a similar range of results, HIF-2α displayed more expression in the proximal portion 
of the varicose vein than the distal portion when comparing median values, but this data was 
not significant. However, there is a relatively large and similar range of HIF-2α expression in 
the proximal and distal segments and once the samples were paired the medians became 
closer suggesting that there is no regional variation.  
When correlating HIFs with MMP and their inhibitors, HIF-1α displayed a 
statistically significant correlation with MMP-2. In contrast, HIF-2α showed a very 
significant correlation with MT1-MMP. These results would suggest that MMP-2 regulation 
is more likely to be mediated by HIF-1α, whereas MT1-MMP may be regulated by HIF-
2α. Fan et al induced chemical hypoxia by cobalt chloride on rat hepatic stellate cells and 
measured the expression of MMP-2 and HIF-1α in rat hepatic stellate cells. The expression of 
MMP-2 and HIF-1α were increased gradually with the increase of the CoCl2 concentration. 
This would support my correlation and suggest that HIF-1α may play a part in the regulation 
of MMP-2 transcription under hypoxic conditions (Fan et al. 2007). Petrella et al have shown 
direct regulation of MT1-MMP by HIF-2α as well as identifying a functional HIF-binding 
site in the proximal promoter of MT1-MMP (Petrella et al. 2005). Together with my findings 
this is strong evidence to suggest an association between HIF-2α and MT1-MMP.  
When correlating HIFs with the cytokines, HIF-1α showed significant correlation 
with TNF-α and IL-1β, whereas HIF-2α showed very significant correlation with TNF-α.  As 
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mentioned previously there is little data available but this result implies that there is a link 
between HIF-1α and HIF-2α suggesting that the TNF-α expression in likely to involve the 
HIF pathway. Coimbra et al support the suggestion from Hellwig-Burgel et al that the 
cytokines actually stimulate HIF gene expression themselves. They showed that in human 
chondrocytes experiencing up to 16 hours of hypoxic conditions there was a modest 
stabilization and/or an increase of HIF-1α expression. In parallel, treatment of the articular 
chondrocytes with TNF-α resulted in an increase in HIF-1α protein steady state levels under 
normoxic conditions (Coimbra et al. 2004). This would suggest that TNF-α may influence the 
HIF pathway but a reduced oxygen concentration does not have to be present in order for the 
pathway to be activated. HIF-1α also correlated with IL-1β.  
There is no doubt from the literature that HIF-1α is linked with IL-1β. It is unclear 
whether IL-1β stimulates HIF-1α gene dependant expression or whether changes in HIF-1α 
expression affects the expression of IL-1β. An example of the former theory is Jung et al, 
who found that even under normoxic conditions IL-1β up-regulates functional HIF-1α protein 
through a classical inflammatory signalling pathway involving Nuclear Factor Kappa Beta 
and COX-2, consequently causing an up-regulation of VEGF (Jung et al. 2003). In contrast, 
Zhang et al reports that IL-1β shares common features of other known HIF-1α−regulated 
genes and that human IL-1β genes carry multiple HIF-1-binding sites in their promoter 
regions. They suggest that IL-1β is up-regulated by hypoxia and CoCl2 in human and mouse 
astrocytes in parallel with the up-regulation of HIF-1α mRNA and protein (Zhang et al. 
2006). It could be that both these pathways occur independently and are activated separately 
depending on whether the environment is under inflammatory or hypoxic stress. Either of 
these conditions could contribute to the formation of varicose veins. The fact that HIF-1α 
correlated with both TNF-α and IL-1β maybe of interest as these two pro-inflammatory 
cytokines have been documented by more than one to work in synergy with each other 
(Martensson et al. 2004; Gurantz et al. 2005).  
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It is surprising that neither HIF-1α nor HIF-2α correlated with VEGF as there is a 
multitude of data to support the dependence of VEGF expression on HIF-1α (Ozaki et al. 
1999; Hewitson and Schofield 2004; Li and Dai 2004; Dery et al. 2005; Zhang et al. 2009). It 
is known that VEGF is a down-stream target gene of HIF-1α. The fact that there was no 
correlation between HIF-2α and VEGF is less surprising and supports the findings of Carroll 
et al who in addition to reporting that HIF-1α primarily regulates transcriptional activation of 
VEGF in response to hypoxia, they also observed a reciprocal relationship between HIF-1α 
and HIF-2α expression in hypoxia in renal cell carcinoma cells, in that HIF-2α enhanced 
HIF-1α-mediated VEGF (Carroll and Ashcroft 2006). Once again, since HIFs are 
predominantly regulated at the level of protein stability, it may have been informative to also 
measure HIF protein expression and correlate this with VEGF. IL-6 showed no correlation to 
either of the HIFs. 
The frustrations and limitations relating to specimen quantity, type and the difficulty 
with RNA expression discussed in Chapter 3 apply also to this chapter. HIF, especially HIF-
2α, was expressed at very low levels in venous tissue. On a practical level this could be due to 
the primers that were available to me at the time. 
In order to examine further whether hypoxia was indeed a feature of disease and 
potentially contribute to changes in the vessel wall I performed immunohistochemistry of 
varicose vein tissue (proximal and distal specimens) and veins from other sources that were 
stored in formalin. This part of the study has not been included in this thesis as although HIF 
staining in renal cell carcinoma has previously been successful, the staining techniques used 
for venous tissue were still in experimental stages in our department and despite exploring a 
number of methods, the slides were substandard and unable to be analysed. For future studies, 
I would recommend that tissue is also stored in a snap frozen form in order to minimalise the 
potential for the possibility of HIF degradation. 
In summary, I have successfully shown that both HIF-1α and HIF-2α are expressed 
at the mRNA level in varicose veins and that there is a relationship between HIFs and 
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MMP/TIMP, and between HIFs and cytokines. This work suggests an inter-play between 
hypoxia and cytokines in regulating the MMP/TIMP balance. The next part of my project 
(Chapter 5) will again address whether hypoxia alters the expression of MMP or their 
inhibitors on saphenous vein endothelial cells but it will also differentiate the effects of acute 
or chronic hypoxic episodes on these genes of interest. 
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5 REGULATION OF MMP/TIMP BY HYPOXIA IN 
SAPHENOUS ENDOTHELIUM 
 
5.1 INTRODUCTION 
The endothelium lines the lumen of all blood vessels and provides an anti-thrombotic 
surface to protect the underlying smooth muscle cell layer from the potential action of 
leukocytes and platelets (Mantovani et al. 1992), as well as acting as a selectively permeable 
barrier regulating the flow of nutrients, biologically active substances and blood cells across 
the vessel wall (Cines et al. 1998). Endothelial cells can be activated by biochemical or 
biomechanical stimuli, including changes in the environmental oxygen tension, leading to the 
release of factors regulating important functions e.g. vessel diameter, vascular growth and 
repair, leading to changes in the ECM and in immune and inflammatory responses (Gimbrone 
et al. 1997). These responses occur in part via the transcriptional induction of genes, 
specifically, in the case of changes in matrix composition, in genes encoding matrix proteins 
or remodelling molecules such as the MMPs and their inhibitors. It is thought that short term 
exposure of endothelial cells to low oxygen tension results in the elaboration of 
predominantly vasoconstricting effectors whereas longer-term or more severe hypoxia 
generates factors that can induce smooth muscle proliferation and irreversible remodelling of 
the vasculature (Faller 1999). 
The results described so far in my thesis suggest a relationship between hypoxia-
inducible transcription factor family member HIF-1α and MMP-2, and between HIF-2α and 
MT1-MMP. There have certainly been reports of alterations in selected MMP/TIMP 
expression following exposure of endothelial cells to hypoxia. Ottino et al reported changes 
in gene expression for MMP-1, MMP-2, MMP-9, MT1-MMP and TIMP-2 in monkey 
endothelial cells exposed to hypoxia. MMP-2 protein was further evaluated by zymography. 
These authors found that hypoxia triggered a 3-fold increase in the gene expression of MT1-
MMP, MMP-2 and TIMP-2, and a 10-fold increase in MMP-2 levels. Expression of MMP-1 
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and MMP-9 mRNA was not detected (Ottino et al. 2004). Ben-Yosef et al performed a 
number of studies investigating the effect of hypoxia and re-oxygenation on endothelial cells, 
using both human umbilical vein endothelial cells (HUVEC) and human macrovascular 
endothelial cells (EAhy 926), and studying MMPs and their inhibitors. Interestingly they have 
shown that an acute hypoxic episode of 6 hours decreased the expression of MMP-2, MT1-
MMP and TIMP-2. This also caused a reduced latent and active MMP-2 protein. However 
chronic hypoxia further suppressed MT1-MMP and TIMP-2 expression but resulted in a 
marked increase in MMP-2 expression and enzyme secretion was observed. This suggests that 
MMP-2 interactions with ECM during episodes of hypoxia are likely to occur independently 
of MT1-MMP and TIMP-2 (Ben-Yosef et al. 2002; Ben-Yosef et al. 2005).  
In contrast, there have been other studies on different types of endothelial cells that 
do not support the above findings. For example, Ye at al found that a 24 hour period of 
hypoxia caused a significant decrease in the protein content and activity of MMP-2 (Ye et al. 
2005) in porcine pulmonary artery endothelial cells. Noda et al reported a 2.3-fold increase in 
MT1-MMP expression in rabbit retinal glial cells under hypoxic conditions (Noda et al. 
2005).  As briefly discussed, hypoxia could affect endothelial cells in varicose vein disease as 
a result of haemodynamic changes causing macrocirulatory ischemia damaging the 
endothelial cells of the intima and/or hypoxia to the endothelial wall caused by insufficient 
supply by the vasa vasorum in the adventitia. 
 
5.2 OBJECTIVES 
Evidence has shown that the degree of hypoxia effects endothelial cells in a 
differential manner. I aimed to investigate the effects of hypoxia on venous endothelial cells 
in terms of the expression of MMP and their inhibitors. In this study, potential alterations in 
MMP/TIMP expression were examined under differing hypoxic conditions, namely acute and 
chronic hypoxia. 
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5.3 MATERIALS AND METHODS 
5.3.1 CELL EXTRACTION AND CULTURE 
Human Saphenous Vascular Endothelial Cells (HSVEC) were obtained by enzymatic 
release from saphenous veins harvested during high ligation of varicose veins or bypass 
surgery and then immortalised and cultured as described previously in Materials and 
Methods. HMEC-1 (SV40 T antigen transformed dermal endothelial cells derived from 
human foreskin, pulmonary and hepatic endothelium, which retain microvascular endothelial 
cell characteristics) were also cultured as explained in the same section. 
5.3.2 HYPOXIC EXPOSURE 
The cells were exposed to differing degrees of oxygen concentration in the RS 
Biotech Galaxy R incubator over a 24 hour period. The protocol for this is explained in full in 
Chapter 2. HSVEC and HMEC-1 had three identical flasks of confluent cells. One flask under 
went 24 hours in normoxic conditions, the other acute hypoxia (6 hours 1% oxygen followed 
by 18 hours normoxia) and the last chronic hypoxia (24 hours 1% oxygen). Triplicates were 
completed for each experiment.  
5.3.3 RNA EXTRACTION AND QUANTITATION 
On completion of hypoxic exposure, RNA was extracted from the cells using the 
QIAamp RNA blood mini kit (QIAGEN) method. GAPDH PCR was performed in order to 
confirm the absence of genomic DNA. RNA was then quantified using a spectrophotometer 
and 500ng of RNA was used from each set of cultures and subjected a reverse transcription 
reaction to prepare cDNA. GAPDH PCR was then performed in order to confirm the presence 
of cDNA. Quantitative PCR using a Sybr Green Jumpstart Taq Readymix allowed sequential 
quantitative PCR runs to analyse the genes of interest. These included MMP-2, MT1-MMP, 
TIMP-2 and TIMP-3. 
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5.3.4 STATISTICAL ANALYSIS 
The data was collected on the Rotor-gene 7 program in order to set a threshold and 
obtain the Ct values. These were then collated on to an Excel spread sheet and calculations 
made using comparative Ct method, also called 2-ΔΔCt method (see Chapter 2). The mRNA 
levels were then compared and statistically analysed in the HSVEC populations and the 
HMEC-1 using GraphPad Prism version 4.03 software. 
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5.4 RESULTS  
The following analyses were performed  
i) Total mRNA levels in each individual population of HSVEC expressed relative 
to normoxia 
ii) Total mRNA levels of all 3 HSVEC populations expressed relative to normoxia 
iii) Total mRNA levels of all 3 HMEC populations expressed relative to normoxia 
5.4.1 MMP-2 EXPRESSION IN DIFFERENT ENDOTHELIAL CELL LINES 
MMP-2 mRNA levels were quantified by PCR in HSVEC and HMEC-1. MMP-2 
mRNA was present in both HSVEC and HMEC-1. Analysing the 3 individual populations of 
HSVEC, it was apparent that MMP-2 mRNA was more abundant in the acute hypoxic models 
and chronic hypoxic models than those that were maintained in a normoxic state. However, 
there was no significant difference between responses induced by acute versus chronic 
hypoxia when analysed using unpaired t-test (p=0.8452, p=0.1633, p=0.2067 respectively for 
Figure 5.1 i, ii and iii). When all data were compared, it was also clear that there was an 
increased expression of MMP-2 mRNA in cells that were exposed to acute hypoxia when 
compared to cells that underwent the chronic hypoxic protocol (Figure 5.2). However, this 
also was not significant using a paired t-test (p=0.0750). When comparing values for MMP-2 
mRNA levels in the HMEC-1, cell line experiencing acute or chronic hypoxia, these appeared 
to follow a similar pattern to the HSVEC (Figure 5.3), in that there was an increased amount 
of MMP-2 mRNA expression in acute hypoxia (mean fold increase=472.837) when compared 
to chronic hypoxia (mean fold increase=55.629), but this difference was not significant using 
an unpaired t-test (p=0.3019). 
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Figure 5.1 MMP-2 mRNA levels in HSVEC during differing exposures to hypoxia 
MMP-2 mRNA levels in the 3 different populations of HSVEC exposed to either acute or chronic 
hypoxia, expressed relative to normoxia. Data are expressed as mean +/- mean. 
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Figure 5.2 MMP-2 mRNA levels in paired HSVEC during exposures to acute and 
chronic hypoxia 
MMP-2 mRNA levels in 3 populations of HSVEC exposed to either acute or chronic hypoxia, 
expressed relative to normoxia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 MMP-2 mRNA levels in HMEC-1 during differing exposures to hypoxia 
MMP-2 mRNA levels in the 3 populations of HMEC-1 cells exposed to either acute or chronic 
hypoxia, expressed relative to normoxia. Data are mean and individual values. 
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5.4.2 MT1-MMP EXPRESSION IN DIFFERENT ENDOTHELIAL CELL LINES 
MT1-MMP mRNA levels were quantified by PCR in the HSVEC and HMEC-1. 
MT1-MMP mRNA was present in both HSVEC and HMEC-1. Analysing the 3 individual 
populations of HSVEC, it was apparent that MT1-MMP mRNA was more abundant in acute 
hypoxia than under normoxic conditions (Figure 5.4). However, the chronic hypoxic model 
showed a variable response. In one population there was more MT1-MMP mRNA expression 
under chronic hypoxia than in acute hypoxia (Figure 5.4i), although both showed more MT1-
MMP expression than under normoxia. This data was not significant using an unpaired t-test 
(p=0.6364 for acute versus chronic hypoxia). The other 2 populations showed a large 
reduction in the amount of MT1-MMP mRNA expression under chronic hypoxia when 
compared to acute hypoxia, and indeed even a reduced amount when compared to normoxic 
model. This data was significant using unpaired t-test (for acute versus chronic hypoxia 
p=0.0187, p=0.0480 for Figure 5.4 ii and iii respectively). These trends are also apparent in 
Figure 5.5 when all data are compared. However, when data was paired, it was statistically 
non-significant (p=0.5042). When comparing the mean values for MT1-MMP mRNA levels 
in the HMEC-1, experiencing acute or chronic hypoxia, these follow a similar pattern to the 
HSVEC (Figure 5.6). There was an increased amount of MT1-MMP mRNA expression in the 
acute hypoxic model (mean fold change relative to normoxia=2.748) when compared to the 
chronic model (mean fold change relative to normoxia=0.0690). This data was not significant 
using an unpaired t-test (p=0.2650). 
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Figure 5.4 MT1-MMP mRNA levels in HSVEC during differing exposures to 
hypoxia 
MT1-MMP mRNA levels in the 3 different populations of HSVEC exposed to either acute or chronic 
hypoxia, expressed relative to normoxia. Data are expressed as mean +/- mean. 
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Figure 5.5 MT1-MMP mRNA levels in paired HSVEC during exposures to acute 
and chronic hypoxia 
MT1-MMP mRNA levels in 3 populations of HSVEC, expressed relative to normoxia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 MT1-MMP mRNA levels in HMEC-1 during differing exposures to 
hypoxia 
MT1-MMP mRNA levels in the 3 populations of HMEC-1 cells, expressed relative to normoxia. Data 
are mean and individual values. 
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5.4.3 TIMP-2 EXPRESSION IN DIFFERENT ENDOTHELIAL CELL LINES 
Similarly, TIMP-2 mRNA levels were quantified by PCR in the HSVEC and HMEC-
1. TIMP-2 mRNA was present in both HSVEC and HMEC-1. Analysing the 3 individual 
populations of HSVEC there appeared to be little difference in TIMP-2 mRNA expression 
between the 3 different models (Figure 5.7). Statistical analyses were performed on all 3 
populations using unpaired t-test and unsurprisingly none of the tests were significant (for 
acute versus chronic hypoxia p=0.0833, p=0.0826, p=0.3754 for Figure 5.7 i, ii and iii 
respectively). When this data was paired a subtle trend was visualised, in that there tended to 
be slightly more TIMP-2 mRNA in acute hypoxia than under chronic hypoxia (Figure 5.8). 
This trend was not significant using a paired t-test (p=0.0833). When comparing the mean 
values for TIMP-2 mRNA levels in the HMEC-1, experiencing acute or chronic hypoxia, it 
showed a similar, but more convincing, pattern to the HSVEC (Figure 5.9). There was an 
increased amount of TIMP-2 mRNA expression in the acute hypoxic model (mean fold 
change relative to normoxia=26.906) when compared to the chronic model (mean=5.470). 
This data was not significant using an unpaired t-test (p=0.1999). 
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Figure 5.7 TIMP-2 mRNA levels in HSVEC during differing exposures to hypoxia 
TIMP-2 mRNA levels in the 3 different populations of HSVEC exposed to either acute or chronic 
hypoxia, expressed relative to normoxia. Data are expressed as mean +/- mean. 
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Figure 5.8 TIMP-2 mRNA levels in paired HSVEC during exposures to acute and 
chronic hypoxia 
TIMP-2 mRNA levels in pooled 3 populations of HSVEC, expressed relative to normoxia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 TIMP-2 mRNA levels in HMEC-1 during differing exposures to hypoxia 
TIMP-2 mRNA levels in the 3 populations of HMEC-1 cells, expressed relative to normoxia. Data are 
mean and individual values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ac
ute
 H
yp
ox
ia
Ch
ro
nic
 H
yp
ox
ia
0
1
2
3
4
Paired t test
  P value
  P value summary
0.0833
ns
Fo
ld
 c
ha
ng
e 
w
ith
 r
es
pe
ct
to
 n
or
m
ox
ia
Ac
ute
 H
yp
ox
ia
Ch
ro
nic
 H
yp
ox
ia
0
10
20
30
40
50
60
Unpaired t test
  P value
  P value summary
0.1999
ns
Fo
ld
 c
ha
ng
e 
w
ith
 r
es
pe
ct
to
 n
or
m
ox
ia
MD (Res) Thesis Beverley Saunders 
Chapter 5 
 141
5.4.4 TIMP-3 EXPRESSION IN DIFFERENT ENDOTHELIAL CELL LINES 
Finally, TIMP-3 mRNA levels were quantified by PCR in the HSVEC and HMECs. 
MMP-2 mRNA was present in both HSVEC and HMEC-1. Analysing the 3 individual 
populations of HSVEC it was interesting that TIMP-3 mRNA was more abundant in the 
chronic hypoxic models than in acute hypoxic models (Figure 5.10). This is a reverse trend in 
comparison to the other genes of interest investigated. When performing statistical analysis on 
the individual populations using unpaired t-test, none of this data was significant (for acute 
versus chronic hypoxia p=0.1888, p=0.0.661, p=0.5149). However, when pairing the samples 
(Figure 5.11) there was a clear trend, in that TIMP-3 mRNA expression was increased with 
increasing hypoxic conditions and this was found to be statistically significant using paired t-
test (p=0.0120). When comparing the mean values for TIMP-3 mRNA levels in HMEC-1 
experiencing acute or chronic hypoxia, this followed a similar pattern to the HSVEC (Figure 
5.12). In contrast to the previous genes of interest examined, there was an increased amount 
of TIMP-3 mRNA expression in the chronic hypoxic model (mean fold change relative to 
normoxia=1.170) when compared to the acute model (mean fold change relative to 
normoxia=0.402). However this data was not significant using an unpaired t-test (p=0.5110). 
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Figure 5.10 TIMP-3 mRNA levels in HSVEC during differing exposures to hypoxia 
TIMP-3 mRNA levels in the 3 different populations of HSVEC exposed to either acute or chronic 
hypoxia, expressed relative to normoxia. Data are expressed as mean +/- mean. 
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Figure 5.11 TIMP-3 mRNA levels in paired HSVEC during exposures to acute and 
chronic hypoxia 
TIMP-3 mRNA levels in 3 pooled populations of HSVEC, expressed relative to normoxia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12 TIMP-3 mRNA levels in HMEC-1 during differing exposures to hypoxia 
TIMP-3 mRNA levels in the 3 populations of HMEC-1 cells, expressed relative to normoxia. Data are 
mean and individual values. 
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5.5 DISCUSSION 
This chapter set out to assess the effect of hypoxia on human saphenous endothelial 
cell expression of MMP and their inhibitors. This was addressed by culturing HSVEC and 
HMEC-1 and exposing them to differing hypoxic environments over a 24 hour period, 
extracting RNA and quantifying and analysing the expression levels for MMP-2, MT1-MMP, 
TIMP-2 and TIMP-3. 
The venous wall is composed of an endothelial lining surrounded by an ECM 
composed of collagen, elastin, SMC, and proteoglycans. The integrity of the structure and 
function of such capacitance vessels is maintained by a delicate balance between the synthesis 
and degradation of these proteins and the ECM (Naoum et al. 2007). Endothelial cells are the 
major determinant of vascular tone, leukocyte adhesion and smooth muscle proliferation and 
under normal circumstances the endothelium maintains a vasodilator, antithrombotic and anti-
inflammatory state. However, when endothelial cells undergo activation, an increase in the 
expression of adhesion molecules such as selectins, vascular cell adhesion molecule-1, and 
intercellular adhesion molecule-1 promotes the adherence of the inflammatory cells 
monocytes, neutrophils, lymphocytes, and macrophages and recruitment of additional 
cytokines, growth factors and MMP (Sprague and Khalil 2009). Taking this into 
consideration it is highly likely that endothelial cells play a large role in the inter-play that is 
likely to occur in the pathogenesis of varicose vein disease. 
The vascular response to hypoxia has multiple components. Short term exposure of 
endothelial cells to low oxygen tension results in the elaboration of predominantly 
vasoconstricting effectors. The endothelium is known to be involved in vasoconstriction 
during hypoxic episodes which suggests that the vascular smooth muscle response during 
hypoxic episodes in regulated by interaction with adjacent endothelial cells. Long term and 
more severe hypoxic exposure generates factors that induce irreversible smooth muscle 
proliferation, remodelling and fibrosis. It is thought that the endothelial cells detect changes in 
oxygen tension through a biochemical sensor and respond by regulating the transcription of 
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genes encoding paracrine vasoactive and mitogenic growth factors (Faller 1999).  
My predecessors reported, in 2001, the successful generation of human saphenous 
vein endothelial cell lines by infection with SV40 large T-antigen or HP16 E6 and E7 genes. 
This cell line provided me with a novel resource as primary cultures of human endothelial 
cells have a short life span in vitro and tend to de-differentiate after 3–4 passages reverting to 
a fibroblastic phenotype (Scoumanne et al. 2002). Previous studies have used endothelial cell 
lines generated from human umbilical vein. Although widely used, human umbilical vein 
endothelial cell lines may have characteristics associated with the limited life span and 
specialised functions of umbilical endothelial cells in vivo. They are commonly thought to be 
a poor model for adult vessel endothelial cells (Garlanda and Dejana 1997) and are therefore 
unlikely to be an appropriate model for the more clinically relevant saphenous vein 
endothelial cells. The only disadvantage to this library of cells was that some cells were 
derived from specimens taken from the GSV harvested during lower limb arterial surgery and 
other cells were cultured from specimens taken during varicose vein surgery. The most 
compatible comparison for our previously prepared HSVEC was HMEC-1 cells. HMEC-1 are 
the first immortalized human microvascular endothelial cell line that has retained the 
morphologic, phenotypic, and functional characteristics of normal human microvascular 
endothelial cells (Ades et al. 1992). 
My results in this chapter have shown that there appears to be a trend of upregulation 
for the MMPs, MMP-2 and MT1-MMP, in endothelial cells when exposed to an acute 
episode of hypoxia. These results were not significant. The expression for these genes was 
less in the chronic model when compared to the acute model. For MMP-2 this result was not 
significant however, when comparing the individual HSVEC populations for MT1-MMP, 2 
cell lines gave a significant result. This significance was lost when the data was paired. These 
results conform with the findings of Ottino et al who researched acute hypoxic exposure on 
monkey choroid-retinal endothelial cells. They found that MMP-2 activity increased 10 fold 
and MT1-MMP expression increased 3 fold when experiencing low oxygen tension for up to 
a maximum of 8 hours (Ottino et al. 2004). In contrast, Ben-Yosef et al found that endothelial 
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cells exposed to a short (6 hour) hypoxic episode inhibited the mRNA expression of MMP-2 
and MT1-MMP, and TIMP-2 and that prolonged (24 hour) hypoxia further suppressed MT1-
MMP mRNA (as shown by my results), whereas it enhanced MMP-2 mRNA (Ben-Yosef et 
al. 2002). 
Although TIMP-2 expression was consistently detected, its abundance during 
normoxic, acute hypoxic and chronic hypoxic conditions remained unremarkable. Riches et al 
had a similar finding when examining the expression of TIMP-2 in normoxic and hypoxic 
myofibroblasts (Riches et al. 2009). TIMP-3 expression, on the other hand, showed little 
change in the acute hypoxic environment but displayed a significant increase in expression 
under chronic hypoxic conditions. The only evidence to support this is from Norman et al 
who examined the effects of hypoxia on MMP/TIMP expression in human renal fibroblasts. 
They found that hypoxia differentially affected expression of the mRNAs for the three 
TIMPs, increasing expression of TIMP-1 and -3 mRNA, while TIMP-2 mRNA levels were 
unaffected (Norman et al. 2000), thus echoing my results. 
This chapter aimed to assess if hypoxia could affect venous endothelial cells and 
subsequently contribute to changes in the vessel wall, thus resulting in pathology. I have 
shown that hypoxic insult on endothelial cells potentially causes alterations in MMP and 
TIMP mRNA expression, to differing degrees. As a comparison, it would have been of 
interest to also assess the effect of hypoxia on cytokine expression in these populations of 
cells. In order to draw a sturdier conclusion and to further investigate the objective of this 
chapter, assessment of protein levels and activity of the MMPs, TIMPs and cytokines would 
be of interest and would give a better indication of alterations that could occur under hypoxic 
conditions. This could be done using Western Blotting or immunohistochemistry. 
HIFs, when stabilized by hypoxic conditions, activate a signalling cascade that results 
in the upregulation of several genes to promote cell survival in low-oxygen conditions. 
Instead of measuring HIF directly, a different approach to studying the effects of hypoxia, is 
to quantify the expression of HIF target genes. Examples of these in endothelial cells would 
MD (Res) Thesis Beverley Saunders 
Chapter 5 
 147
be glucose transporter GLUT-1, carbonic anydrase (CA)-9 and enolase (ENO)-1 and their 
expression could be measured by similar methods to the techniques used in this thesis. 
As discussed previously I have shown that hypoxic insult potentially causes 
alterations in MMP and TIMP mRNA expression in venous endothelial cells. Obviously by 
culturing endothelial cells, the results only portray a small part of what could be happening 
within the vein wall. In order to replicate in vivo conditions, a similar hypoxic experiment 
could be performed using a vein culture model (including venous endothelial cells, fibroblasts 
and SMC) and measurements for mRNA expression or activity levels of MMPs, TIMPs and 
cytokines taken and assessed. However, the pattern of responses between HSVEC and 
HMEC-1 in terms of response to hypoxia was similar, suggesting that whether hypoxia occurs 
in large veins and/or microvessels of the vasa vasorum, a comparable effect in terms of 
MMP/TIMP would be seen. 
Another technique that would be helpful in investigating the pathogenesis of varicose 
vein disease are PCR-based arrays. PCR arrays are the most reliable tool for analyzing the 
expression of a focused panel of genes, in this case hypoxia-related genes. PCR arrays are a 
highly sensitive and specific method, with high amplification efficiencies and high 
reproducibility that profiles the expression of a panel of genes relevant to a particular pathway 
or disease state. 
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6 CONCLUSIONS 
The primary cause of varicose veins is still unknown. Varicose veins are common, 
affecting up to 40% of the population (Golledge and Quigley 2003). Although there are many 
options for treatment, including conservative methods such as support hosiery, surgical 
striping of the GSV is by far the commonest form of treatment for varicose veins, with more 
than 60,000 operations each year in England alone. The reasons for treatment are vast ranging 
from, unsightliness to bleeding or ulceration. This condition is therefore of great importance 
in surgery, as it is a common problem with frequent hideous complications that not only 
physically affect patients lives but impinge greatly on their quality of life. 
This MD (Res) thesis, using gene expression techniques, aimed to assess whether or 
not metalloproteinase (MMP)/tissue inhibitor of MMP (TIMP) contribute to the potential 
changes in the varicose vein disease process by disrupting the normal turnover of the ECM, 
and whether cytokines are also involved in regulating this process. The aim was also to 
investigate whether hypoxia may be a feature of varicose vein disease and this was assessed at 
the mRNA level within varicose vein samples and also by visualising the relationship 
between markers of hypoxia with the MMPs, their inhibitors and cytokines. Endothelial cell 
reaction to acute and chronic hypoxic stress was also assessed with regards to expression of 
MMPs and their inhibitors. 
 
6.1 PREVIOUS WORK 
Research from the Kennedy Institute of Rheumatology (KIR, Faculty of Medicine, 
Imperial College), in collaboration with the Department of Vascular Surgery (Division of 
Surgery, Anaesthetics and Intensive Care, Faculty of Medicine, Imperial College), has 
demonstrated regional variation in varicose vein wall morphology, in the form of 
hypertrophic and atrophic changes. Atrophic changes appear to be more common in the distal 
end of GSVs. Previous studies have been conducted examining the imbalances of 
MMP/TIMP in varicose veins. My predecessor, Mr Biju Aravind, aimed to achieve this 
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objective as well as further analyse the cellular markers on the vein wall which could be 
viewed as possible triggers for the protease imbalance. He collected varicose veins as well as 
veins from other sources. The vein segments were immunostained for MMP-2, MT1-MMP, 
TIMP-2 and TIMP-3. The immunopositivity was then further quantified using image analysis. 
The expression of MT1-MMP and TIMP-3 was shown on the varicose vein wall for the very 
first time. These along with MMP-2 and TIMP-2 appeared to be mostly localised in the SMC. 
When proximal and distal varicose vein wall thickness were compared in the same patients, 
the distal vein walls tended to be thinner. He reported a significantly higher expression of 
MT1-MMP and TIMP-2 in varicose veins in comparison to veins from other sources by 
image analysis. When analysed further there was positive correlation in the expression of 
MT1-MMP and MMP-2 in varicose vein wall (Aravind 2007). 
Furthermore, infiltration of the vein wall in both varicose veins and veins from other 
sources by inflammatory cells that stain positive for CD45 has been demonstrated. CD45 and 
Mast cell tryptase immunopositive cell counts were significantly higher in varicose veins than 
in veins of other sources. CD45 and Mast cell tryptase immunopositive cell counts showed a 
positive correlation with each other.  
To complete his work, Mr Aravind also preliminary performed RNA extraction, 
quantitative PCR and activity assays for MT1-MMP in a very limited number of varicose vein 
specimens, which showed higher MT1-MMP activity in distal varicose veins than proximal 
segments. However there was no significant difference in the MT1-MMP gene expression 
between proximal and distal varicose vein segments. 
Taken together, these data suggested that distal areas of varicose vein wall tended to 
be thinner, and were associated with greater MT1-MMP activity, and reduced inhibitor 
expression (TIMP-2 and TIMP-3) than thicker areas of vein wall, supporting the concept that 
changes in the MMP/TIMP balance may influence varicose vein wall morphology. 
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6.2 DATA DESCRIBED IN THIS THESIS  
I have confirmed that mRNA is expressed for the MMPs and their inhibitors, MMP-2, 
MT1-MMP, TIMP-1 and TIMP-2, in varicose vein tissue. When these were compared to 
veins from other sources there was no difference in the mRNA expression for the MMPs, 
MMP-2 or MT1-MMP. This finding goes against my predecessors image analysis data that 
showed a significantly higher expression of MT1-MMP in varicose vein tissue. However 
there was a significant increase in the amount of mRNA expressed for TIMP-2 and TIMP-3 in 
varicose vein tissue when compared to veins from other sources. These results taken together 
indicate that with no change to MMP-2 and MT1-MMP expression and a significant increase 
in TIMP-2 and TIMP-3 expression there would be an alteration in the MMP/TIMP ratio. This 
would suggest that the MMP/TIMP imbalance could be disrupted by the over-expression of 
TIMP. 
MT1-MMP mRNA was found to have higher mRNA expression levels in distal 
varicose vein segments relative to proximal varicose vein segments although this data was not 
found to be significant. This is consistent with the protein and preliminary data obtained by 
my predecessor. TIMP-2 and TIMP-3 are abundantly expressed in varicose vein tissue. 
TIMP-2 showed a non-significant trend to having increased expression levels (2-fold) in 
distal varicose vein segments than in proximal segments. MMP-2 and TIMP-3 showed no 
regional variation. 
Degradation of the ECM is regulated by proteinases, including MMP, their activators, 
and their inhibitors. Activated MMPs can degrade all ECM components. MMP can be 
regulated at three levels: MMP production in the pro-MMP state, MMP activation and 
inhibition of the activated form of MMP. MMPs are inhibited by TIMPs, which form high-
affinity, essentially irreversible, non-covalent complexes with the active forms of MMP. It is 
important that the activity of MMP is kept under tight regulation to maintain homeostasis and 
therefore keep a healthy ECM. Even though I did not observe  increased expression of MMP-
2, like other researchers have reported, upregulation of TIMP-2 and TIMP-3 in varicose vein 
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tissue maybe enough to upset the MMP/TIMP ratio and in turn disrupt homeostasis. This 
could partially explain the ECM accumulation in varicose veins.  
It is well documented that reflux, a major feature of varicose vein disease, is 
suggested to occur segmentally and progress in an ascending fashion. As previously 
mentioned, my predecessor found that distal varicose vein walls were thinner in diameter than 
proximal samples retrieved from the same patient. This conclusion was not reached, however, 
by Travers et al (Travers et al. 1996). My mRNA data reiterates the results of Mr Aravind. I 
found a difference between MT1-MMP expression in proximal and distal varicose vein 
(reduced expression in the distal portion) and a trend of increased expression of TIMP-2 in 
distal varicose vein segments despite non-significance. Together this would imply that thinner 
varicose vein segments are associated with greater MT1-MMP activity and reduced TIMP-2 
activity that thicker areas of wall supporting the concept that changes in the MMP/TIMP ratio 
may influence varicose vein morphology.  
I have also confirmed that the cytokines VEGF, TNF-α, IL-1β and IL-6 are expressed 
in varicose vein tissue. The mRNA expression for VEGF and TNF-α, was upregulated in 
varicose vein tissue when compared to veins from other sources, 2-fold and 5-fold 
respectively. This data was not significant. In contrast the interleukins IL-1β and IL-6 both 
had a reduction in mRNA expression in varicose vein tissue when compared to veins from 
other sources. For IL-1β this result was significant. 
The TNF-α data hinted that there may be more expression in the proximal portion of 
the varicose vein that in the distal portion when comparing the median values, but this data 
was not significant. The other cytokines showed no evidence of regional variation. 
It is undecided whether inflammation may play a role in the formation of varicose vein 
disease. There have been a number of reports that cross-sectional histological studies have 
revealed monocytes/macrophage infiltrations in both the wall and the valves of the vein. 
Despite this Badier-Commander et al looked at pro-angiogenic cytokines in varicose veins by 
a combined histological, immunohistochemical and biochemical approach. They found that 
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TGFβ1 and FGF-2 were increased in varicose veins but there was no difference in VEGF 
when compared to control specimens. They also noted no inflammatory cells and suggested 
that the cytokine modulation seen was unlikely to be due to an inflammatory reaction (Badier-
Commander et al. 2001). Various cytokines, both pro-angiogenic and pro-inflammatory have 
been shown to be increased in varicose veins or in simulated varicose vein models by 
inducing venous hypertension. My results indicate that cytokines are likely to be involved in 
the pathogenesis of varicose vein disease. The expression of the pro-angiogenic cytokine 
VEGF and pro-inflammatory cytokine TNF-α are increased in varicose vein tissue. However, 
the pro-inflammatory cytokines, IL-1β and IL-6, which, like TNF-α, tend to be involved in 
acute phase inflammatory reactions are decreased in varicose vein tissue when compared to 
veins from other sources.  
There is no literature to suggest that cytokines display any regional variation in 
varicose vein tissue. My results also show no conclusive evidence that regional variation may 
be present. 
VEGF displayed a statistically significant correlation with TIMP-3. It has been 
reported that TIMP-3 blocks the binding of VEGF to VEGF receptor type 2 and inhibits 
downstream signalling and angiogenesis (Qi et al. 2003). Thus an increase in TIMP-3, to 
counter-act the possible pro-angiogenic effects of VEGF, may be a mechanism to regulate 
angiogenesis in varicose vein adventitia. TNF-α showed a significant correlation with MT1-
MMP and TIMP-3 and a very significant correlation with MMP-2 and TIMP-2. IL-1β also 
significantly correlated with MMP-2, MT1-MMP and TIMP-2. As explained above in detail, 
MMP-2, MT1-MMP and TIMP-2 are linked by forming a ternary complex. The fact that both 
TNF-α and IL-1β levels correlate with the expression of the 3 members of this complex, may 
provide evidence that in varicose veins cytokine-mediated assembly of this complex could be 
important in regulating matrix turnover. TNF-α also correlated with TIMP-3. This was not 
surprising as they have a strong link through TACE.  
I have confirmed, for the very first time that, that mRNA for HIF-1α and HIF-2α are 
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expressed in varicose vein tissue.  
When these were compared to veins from other sources the mRNA expression in 
varicose vein tissue was significantly decreased for both HIF-1α and HIF-2α. This was an 
unexpected result because logically if hypoxia is a feature of varicose vein disease one would 
have expected levels of HIF to have increased in comparison to veins from other sources. It is 
known that HIF protein levels increase in hypoxia. The fact that my results showed a 
reduction in HIF mRNA expression could be explained by HIF protein levels increasing 
under the hypoxic conditions but conversely HIF mRNA levels also being actively degraded 
at the same time. This is supported by the existence of aHIF, a natural antisense transcript 
derived from HIF-1α gene sequences that encodes the 3' untranslated region of HIF-1α 
mRNA (Thrash-Bingham and Tartof 1999)). aHIF is thought to cause degradation of HIF 
mRNA. During prolonged hypoxia, HIF-α proteins negatively regulate HIF-1α expression 
through an increase in aHIF and destabilization of HIF-1α mRNA (Uchida et al. 2004). As a 
consequence, elevated HIF protein levels (due to conditions of hypoxia) may be somewhat 
counter-intuitively be accompanied by decreased HIF mRNA levels. This has been shown to 
be the case in our laboratory in a range of other cell types, particularly after prolonged 
exposure to hypoxia, as might be expected to be the case in varicose veins, and could well be 
a mechanism to control HIF levels in vivo and prevent excessive HIF-mediated gene 
transcription. 
When analysing data comparing proximal versus distal varicose vein samples, neither 
HIF-1α nor HIF-2α showed any difference between the two anatomical areas.   
When correlating HIFs with MMP and their inhibitors, HIF-1α displayed a 
statistically significant correlation with MMP-2. This would suggest that MMP-2 regulation is 
likely to be modulated by HIF-1α. In contrast, HIF-2α showed a very significant correlation 
with MT1-MMP. It is thought that not only does MT1-MMP have a functional HIF-binding 
site in its proximal promoter region but MT1-MMP is under direct regulation by HIF-2α. 
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When correlating HIFs with the cytokines, both HIFs correlated significantly with 
TNF-α. Cytokines appear to stimulate HIF gene expression and it is likely that TNF-α does it 
independently to that of the HIF pathway. It is surprising that neither HIF-1α nor HIF-2α did 
not correlate with VEGF as there is a multitude of data to support the dependence of VEGF 
expression on HIF. Once again, since HIFs are predominantly regulated at the level of protein 
stability, it may have been informative to also measure HIF protein expression and correlate 
this with VEGF.  
There appears to be a trend of upregulation for the MMPs, MMP-2 and MT1-MMP in 
endothelial cells when exposed to an acute episode of hypoxia. These results were not 
significant. The expression for these genes was less in the chronic model when compared to 
the acute model. For MMP-2 this result was not significant however, when comparing the 
individual HSVEC populations for MT1-MMP, 2 cell lines gave a significant result. This 
significance was lost when the data was paired. Although TIMP-2 expression was 
consistently detected, its abundance during normoxic, acute hypoxic and chronic hypoxic 
conditions remained unremarkable. TIMP-3 expression, on the other hand, showed little 
change in the acute hypoxic environment. However, TIMP-3 displayed a significant increase 
in expression under chronic hypoxic conditions. Taken together, these results suggest that 
endoluminal hypoxia may participate in the pathogenesis of varicose vein disease. Venous 
hypertension, blood stasis and alterations in blood flow may have a direct influence on the 
endothelial cells that in turn alter the configuration of MMPs/TIMPs and potentially have 
consequential effects in the deeper layers of the vein wall.  
 
6.3 CLINICAL IMPLICATIONS 
Hypoxia induces activation of HIF in almost all cell types, which results in induction of 
several HIF target genes, involved in cell metabolism, survival, angiogenesis and invasion. It 
is well established that the hypoxia/HIF-VEGF-angiogenesis pathway plays a very important 
role in tumour development and progression. Therefore the development of small molecule 
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inhibitors are targeting hypoxia and HIF, often in combination with conventional 
chemotherapy, has become more and more attractive. In the last years many studies have 
characterised agents which inhibit HIF-1 and angiogenesis, and a number of these compounds 
are currently in clinical trials, or are already approved for the treatment of cancer (reviewed in 
(Semenza 2007). Some of these might be useful for treatment of varicose vein disease. 
For example, In 2002, Rapisarda et al developed a cell-based study to identify small 
molecule inhibitors of the HIF-1 pathway, which may have anti-angiogenic and anti-cancer 
activities. The investigators genetically modified a human glioma cell line to express a 
luciferase reporter gene under control of three canonical copies of HRE, and screened 2000 
small molecule chemotherapeutic agents of the National Cancer Institute Diversity Set. This 
screen identified topoisomerase inhibitors, such as topotecan and camptothecin analogues, as 
being capable of repressing HIF activity and inhibiting transcription of well characterized HIF 
target genes, including VEGF (Rapisarda et al. 2002). Many studies have followed and 
topotecan and camptothecin analogues are currently approved agents for the treatment of 
cancer. Similarly, histone deacetylase enzyme (HDAC) 1 has been reported to be hypoxia-
inducible and to stimulate angiogenesis in vitro and in vivo, suggesting a significant role for 
HDAC in hypoxia-induced angiogenesis. The acetylation of histones by histone 
acetyltransferase and the deacetylation by HDAC has a significant role in regulation of gene 
transcription in many cell types (Grunstein 1997). The deregulation of HDAC activity and 
recruitment to promoters appears to be one of the mechanisms by which these enzymes 
contribute to tumourigenesis (Cress and Seto 2000). Therefore, HDAC inhibitors with 
different chemical structures have been developed as novel anti-tumour agents. 
Finally, in 2003 Mabjeesh et al reported that the endogenous oestrogen metabolite 2-
methoxyestradiol (2ME2) downregulates HIF at the post-transcriptional level and inhibits 
HIF-1-induced transcriptional activation of VEGF expression, establishing 2ME2 as a small 
molecule inhibitor of HIF-1 (Mabjeesh et al. 2003). 2ME2 is currently being evaluated in 
clinical trials for the treatment of solid tumours and is undergoing pre-clinical evaluation for 
inflammatory conditions. 
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6.4 FUTURE WORK 
There have been very few studies examining the contribution of changes in oxygen 
tension to varicose vein disease. This is somewhat surprising, since varicose veins by nature 
involve alterations in blood flow and venous stasis, which must compromise tissue 
oxygenation, and hence is likely to involve alteration in HIF expression. 
I have successfully shown that both HIF-1α and HIF-2α are expressed at the mRNA 
level in varicose veins and that there is a relationship between HIFs and MMP/TIMP, and 
between HIFs and cytokines. My research provided some surprising results. Both HIF-1α and 
HIF-2α showed a significant reduction in expression in varicose vein tissue when compared 
to veins from other sources. However, as described earlier, the major pathway regulating HIF-
1 activity is not through changes in mRNA, but via the oxygen-dependent degradation 
domain in the α-subunit of HIF protein which is the target of specific HIF-α PHD enzymes. 
These enzymes require both O2 and Fe2+, and they have been considered to function as direct 
cellular oxygen sensors, with no intermediate signalling required for HIF regulation. In the 
presence of O2, HIF-α subunits are prolyl hydroxylated on Pro-402 and Pro-564 (in the case 
of HIF-1) and these hydroxyl-proline residues are required for the interaction with the von 
Hippel-Lindau tumour suppressor protein (pVHL), which subsequently guides ubiquitin E3 
ligases to polyubiquitinate HIF-α. Once polyubiquitinated, HIF-α-subunits are targeted for 
proteasomal degradation by the 26S-proteasome. During hypoxia the decline in oxygen levels 
decreases the activity of the PHDs, thereby preventing proline and asparagine hydroxylation 
of HIF-1α. Consequently pVHL cannot target HIF-α for degradation, allowing HIF-α to 
accumulate and dimerise with HIF-1β in the nucleus. This complex recognises and binds to 
HRE in the promoter or enhancer regions of various hypoxia-responsive target genes (Figure 
1.5). Thus, investigation of the mRNA levels of HIF-1α and HIF-2α should be complemented 
by studies of HIF-1α and HIF-2α protein using either immunohistochemistry or Western 
blotting techniques, to conclusively assess whether hypoxia in varicose veins leads to 
upregulation of HIF protein. 
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This thesis used whole vein tissue to assess gene expression. In addition to this data, 
gene expression of specific cells, such as venous endothelial cells, would have been useful as 
this would have provided specific information about the differing features of the vein wall. A 
suitable method to isolate specific cells is laser capture microdissection, which during sample 
collection does not alter or damage the morphology or chemistry of the cells (Orba et 
al.2003). Alternatively, in situ hybridisation could have been used to study gene expression in 
endothelial cells using whole tissue samples. 
Furthermore, as mentioned above, aHIF induction by hypoxia may contribute to 
decreased HIF mRNA levels, and it would therefore be of interest to also measure aHIF 
mRNA levels in vein tissue. During hypoxia, the HIF-1α proteins that are produced, as a 
subsequent effect of increased expression of HIF-α, cause an increase in aHIF production in 
order to negatively regulate HIF. aHIF then encodes the 3' untranslated region of HIF-1α 
mRNA causing it to degrade. Interpretation of HIF mRNA expression is, therefore, not a fair 
representation of what may truly be occurring in varicose vein tissue. There are a number of 
techniques that could be performed in order to verify this preliminary data. 
Importantly, as mentioned above, the accumulation of HIFs results in the activity of 
various hypoxia-responsive target genes. In the case of varicose veins these include VEGF, 
GLUT-1, ENO-1 and CA-9. A more reliable way of assessing HIF expression in varicose 
veins could be to quantify the expression of HIF target genes. In parallel, the protein 
expression and activity levels for HIF could also be evaluated This could then be compared to 
protein analysis for MMP/TIMP and cytokines. 
Hypoxic stress appears to cause alterations in MMP and TIMP mRNA expression in 
venous endothelial cells. While my study described in Chapter 5 focused on endothelial cells, 
the endothelium is just a small component of the vein wall. In order to reproduce a more 
accurate model in order to simulate varicose vein conditions, a similar hypoxic experiment 
could be performed on a vein culture model (including venous endothelial cells, fibroblasts 
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and SMC) followed by measurements for mRNA expression or activity levels of MMPs, 
TIMPs and cytokines taken and assessed. 
Finally, there is no evidence to suggest where the hypoxic insult may occur in the 
vein. Venous hypertension and alterations to blood flow obviously contribute largely to the 
multi-factorial pathology of this disease. It may be that this blood flow modification changes 
the oxygen tension within the blood itself resulting in a direct effect on the endothelial cells. 
A clinical experiment could directly measure venous oxygen levels in varicose vein patients 
and controls. Blood could be taken from the distal segment of GSVs at the medial malleolus 
in both varicose vein patients and controls (matched demographically and selected randomly 
from patients requiring acute surgical assessment). It would be transferred into an arterial 
blood gas syringe and analysed on a blood gas machine for the partial pressure of oxygen and 
pH, to allow determination of oxygen levels. 
 
6.5 SUMMARY OF FINDINGS PRESENTED IN THIS THESIS 
In summary, the aetiology of varicose veins remains unclear. There is increasing 
evidence that alteration of the vein wall is the primary abnormality of the disease. Numerous 
changes in the cellular and ECM components of the vein wall have been demonstrated 
including intimal hyperplasia, SMC proliferation, changes of collagen and elastin content, and 
imbalances of MMPs and their endogenous tissue inhibitors TIMPs. The overall effects 
include relaxation and weakening of the vein wall leading to venous dilatation and reflux 
However, the cause of these changes remains unknown and several factors including vein 
wall hypoxia have been proposed to contribute to the development of varicose veins. The 
following summarise the main findings and conclusions presented in this thesis: 
• I found a significant increase in the amount of mRNA expressed for TIMP-2 
and TIMP-3 in varicose vein tissue when compared to veins from other sources. 
This overexpression of TIMP may be accountable for disruption of the 
MMP/TIMP ratio and in turn affects homeostasis and the ECM. 
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• I would suggest that TIMP-2 and MT1-MMP have an association with each 
other that is independent of MMP-2 and the formation of a ternary complex 
between these 3 molecules. Potentially TIMP-2 binding to MT1-MMP activates 
an extracellular pathway which up-regulates cell proliferation and migration. 
• HIF-1α and HIF-2α are expressed in both varicose and non-varicose veins and 
show no regional variation.  
• HIF-1α significantly correlated with MMP-2 as well as with TNF-α and IL-1β. 
In contrast, HIF-2α showed significant correlation with MT1-MMP and TNF-α 
suggesting an inter-play between hypoxia and cytokines in regulating the 
MMP/TIMP balance. 
• Endothelial cells under hypoxic stress show alterations in MMP/TIMP 
expression might not only damage the cells directly, for example by induction 
of apoptosis, but could potentially have consequential effects in the deeper 
layers of the vein wall. 
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